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ABSTRACT 
Using Immune Modulators to Ameliorate Aleutian Disease in Mink 
by 
Kie Hoon Jung, Doctor of Philosophy 
Utah State University, 2003 
Major Professor: Dr. Edmund D. Brodie, Jr. 
Department: Biology 
iii 
Aleutian disease of mink (AD) is an immunopathological disorder induced by 
persistent infection with AD virus. Many breeds of mink seem to have a high 
susceptibility to AD. Interestingly, the primary feature of AD in susceptible adult mink is 
a chronic, fatal immune complex-mediated glomerulonephritis comparable to that seen in 
human diseases such as systemic lupus erythematosus. Because of its comparative 
aspects to human diseases and the substantial economic loss to the fur industries in the 
world, classical AD and the nature of the virus has been studied extensively for three 
decades. Currently no therapies are available and vaccination has been a failure; the 
latter exacerbated the disease. 
The hypothesis tested in this research was that the treatment of AD-infected mink 
with TGF-~ 1 and dehydroepiandrosterone (DHEA) inhibited or ameliorated the disease. 
The hypothesis was tested by evaluating the effects of TGF-fh and epiandrostene-like 
compounds on the immune response of AD-infected animals on the normal physiological 
parameters of animals and by evaluating the effects of both compounds on virus loads. 
IV 
The TGF-r31 study was designed to evaluate three different doses (200, 100 and 
1 ng/kg) of recombinant human TGF-r31 and one dose (500 ng/kg) of TGF-r3~ inhibitor at 
three different times (treated TGF-r31 2 weeks pre-, 8 hours post-, and 2 weeks post-virus 
inoculation) of administration relative to virus exposure. Animals were administered 
drug or placebo intravenously via the inguinal vein injection and animals were held to up 
to 9 months. 
For the epiandrosterone study, five mink received 16 ng/kg HE2300 once per 
week, 17 animals received 16 ng/kg HE2300 three times per week, and five animals were 
injected with 16 ng/kg HE2500 three times per week. In addition, 17 animals received 
vehicle three times per week. All treatments were injected subcutaneously into the nape 
of the neck of the mink. Animals were held to up to 8 months. 
Pathological analysis of various physical, physiological and immunological 
parameters in surviving mink treated with either immunomodulator (treated with TGF-r31 
at 100 ng/kg and treated with HE2300 at 16 ng/kg three times per week) revealed that 
these parameters were near the levels measured for normal uninfected mink. In contrast, 
in untreated infected animals the measured virus pathology, and physiological and 
immunological parameters were significantly different from the untreated control 
animals. In a comparison of survival times, treated animals with either 
immunomodulator survived almost twice as long as untreated animals. A polymerase 
chain reaction (PCR) assay of lymph node tissue confirmed that AD-infected animals 
treated with either immunomodulator had significantly lower levels of virus DNA than 
untreated infected animals. 
These findings support the hypothesis that TGF-~ 1 and DHEA and its analogs 
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Aleutian disease (AD) is an immunopathological disorder of mink induced by 
persistent infection with AD virus (ADV), a naturally occurring infection caused by a 
virus from the Parvoviridae family (Porter et al., 1980). The chronic infection often leads 
to immune complex disease and is marked by a progressive renal failure. It is 
characterized by a hypergammaglobulinemia, a large fraction of which consists of 
antibody complexed with non-neutralizable virus. Pathological findings include 
mesangial proliferative glomerulonephritis and severe interstitial nephritis comparable to 
that seen in human diseases such as systemic lupus erythematosus (Bloom et al., 1994). 
AD often leads to tremendous weight loss and premature death, both of which severely 
impact the profitability of mink farming 
Currently no therapies are available and vaccination has been a failure; it 
exacerbated the disease (Bloom et al., 1994). For producers who have AD in their mink 
herds, their only recourse is to pelt all animals or to take a chance that the disease will not 
afflict a significant portion of their animals. Therefore, a modality needs to be developed 
that could boost the susceptible animals' immune responses in an appropriate manner to 
allow mink to survive AD. Such a treatment would allow the mink industry to remain a 
profitable endeavor. 
Extensive studies suggest that there is a genetic predisposition to AD. Some mink 
breeds, like those designated as sapphires or having dark coat color, are much more 
2 
susceptible to chronic lethal AD than other breeds such as the wild type strains (Bloom 
et al., 1994). In addition, many immunological studies have suggested that a'n abnormal 
immune response in susceptible animals may cause the pathology of AD (reviewed by 
Aasted and Leslie, 1991; Mori et al., 1991; Kanno et al., 1992; Bloom et al., 1994). 
There are two kinds of immune responses based on the cytokine profile expressed 
during immune response. Thl type cells are involved in inflammatory responses, release 
of interferon gamma (IFN-y), interleukin-6 (IL-6), and tumor necrosis factors (TNF-a, ~), 
activation of macrophages, induction of CD8+ cytolylic T-cells and clearance of viral and 
intracellular infection. Th2 cells are involved in the anti-inflammatory responses and in 
stimulating antibody production by B-cells. In addition, Th2 type cells do not promote 
tissue damage as do Thl cells, the damage by these latter cells being mediated by release 
oflL-3, 4, 5, 6 and 10. A Thl predominance leads to the suppression of Thl cytokines 
such as IL-12 and IFN-y. 
From early studies of AD (Hahn and Hahn, 1983; Bloom et al., 1994), it is 
apparent that the immunological response to AD is overwhelming humoral 
(hypergammmaglobulinemia) and mediated by Th2 type cytokines, especially IL-6. 
Perhaps not coincidentally, human diseases (e.g., Castleman's disease) that are 
characterized by hypergammaglobulinemia are also associated with high levels of IL-6 
production. Based on these findings, AD may be a virus-induced cytokine disorder; a 
syndrome of chronic, inappropriate production of IL-6 and perhaps other Th2-type 
cytokines (Bloom et al., 1994). Perhaps, if one could modulate the immune response in 
AD-infected animals to a largely cell-mediated response with Thl-type cytokines instead 
of the typical Th2 cytokine response, the severity of AD might be diminished or perhaps 
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even prevented. A pertinent observation for the treatment of AD in mink is that an 
attenuated vaccine only enhances AD (a Th2 response), leading to an especially extreme 
B cell hyperplasia, while immunosuppressive therapy has been shown to slightly 
ameliorate the severity of disease, e.g., preventing AD lesions (Cheema et al., 1972). 
One of the compounds chosen, levamisole, does not directly modulate the B cell function 
of producing antibody (Amery and Harig, 1984). The other compound, isoprinosine, 
actually enhances B cell antibody production in the presence of pokeweed mitogen 
(Tsang et al., 1984). Thisa result is not a desirable effect in AD, where over-production 
of antibody leads to fatal disease. 
There is considerable evidence for an immunomodulatory role for a cytokine, 
transforming growth factor beta (TGF-~). It both potentiates and inhibits various 
functions of the immune system in its regulatory role, depending on when and where it is 
expressed. Therefore, the regulatory functions ascribed to TGF-~ sometimes appear to be 
in opposition. However, its potent effects on immune cells in vitro are reflected in the 
various effects it has in a variety of animal model systems, strongly suggesting an 
important role in immune disorders such as autoimmune disease (Derynck and Choy, 
1998). 
A finding relevant to the potential immunotherapy of AD is that exogenous 
administration of TGF-~ in vivo markedly depresses inflammatory and immunological 
responses. For example, TGF-~ delays the onset of experimentally-induced arthritis in 
mice, a disorder involving immune complexes (Brandes et al., 1991). In addition, TGF-
~ also regulates expression of primary antigen presenting cells, which activate T-
lymphocyte responses (Steinman, 1991) that are responsible for correct processing of 
4 
virus antigen. Thus, it is conceivable that TGF-13 could elicit a Th 1 response adequate 
enough to ameliorate AD by inducing appropriate processing of AD antigen.· Finally, 
TGF-131 seems to potently inhibit cell proliferation and is able to induce apoptosis 
(programmed cell death) in B cells (Gordon et al., 1994) in addition to reducing the 
secretion of immunoglobulin from activated B cells (Stavnezer, 1996). These 
mechanisms suggest that TGF-131 may be able to down-regulate what appears to be a B 
cell hyper-response such as is seen in mink with AD. 
Another set of compounds that appear to have useful immunomodulatory 
properties is dehydroepiandrosterone (DHEA) and its analogs. DHEA has been shown 
to have immunomodulating effects in several experimental infections involving viruses 
and protozoans (Rasmussen et al., 1991; Mulder et al., 1992; Uozumi et al., 1996; Loria 
and Padgett, 1998). In HIV infections, 16a-bromoepiandrosterone (a-epi-Br), an analog 
of DHEA, may have shifted cytokine production to a Thl response and increased 
circulating activated immune effecter cells (Freilich et al., 2000). This activity appeared 
not to be androgenic, since the compound only bound weakly to the androgen receptor. 
Thus, DHEA and its analogs and TGF-131 may be able to promote Thl cytokine-type 
responses that could afford protection for mink from chronic lethal AD. 
Therefore, we attempted to develop several approaches for treating experimental 
AD using TGF-131 and epiandrosterone analogs. We tested the hypothesis that treatment 
of AD-infected mink with TGF-131 or epiandrosterone-like compounds would ameliorate 
the development of the AD as shown by enhanced survival time of the animals. 
Literature Review 
This review considers several aspects of a Aleutian disease (AD). After an 
overview of current information about the structure and function of the AD virus (ADV) 
genome, the major clinical forms of AD are discussed. This is followed by summary of 
recent pathogenesis studies providing potential insight into the genesis of the immune 
disorder. 
Aleutian Disease of Mink 
AD is an immunopathological disorder of mink induced by persistent infection 
with ADV (Porter et al., 1980). It is a naturally occurring virus infection caused by a 
virus from the family Parvoviridae. The virus can be detected in saliva, urine, and feces 
and the virus can persist for long periods in the environment. During the virus life cycle, 
certain obligate intermediates of ADV replication are produced. These include 
replicative forms of ADV DNA, viral messenger RNA (mRNA), various proteins, 
progeny genomes, and infectious progeny virus (Bloom et al., 1994). A major goal of 
ADV research is to relate virus infection to the pathogenesis of the clinical syndromes. 
AD is a persistent viral infection of mink. In the early 1940's a spontaneous 
mutation resulting in a dark blue coat color occurred in ranch-raised mink in Oregon and 
was designated the Aleutian mink coat color (Alexandersen, 1986); this mutation is 
homozygous recessive for the Aleutian gene a. In the early 1950' s, as the Aleutian mink 
were continuously in- bred, a chronic wasting disease was noticed in many of them. It 
was mainly characterized by weight loss but on occasion some mink would have 
abnormal hemorrhaging from the mucous membranes. A syndrome involving the 
5 
6 
kidneys, the liver and lymphoid tissue of aa mink was reported, and was referred to as 
AD (Hartsough and Gorham, 1956). It first seemed that only Aleutian mink 'were 
affected; however, it has been subsequently shown that all genotypes of mink are 
susceptible to the disease, but mink homozygous for a gene develop more severe disease 
with a more rapid course. Mortality from AD can be as high as 100% in Aleutian mink. 
The disease is not as severe in other breeds. Wild-type mink known as demi (brown), are 
least affected, with about a 6% mortality. It appears that a small percentage of non-
Aleutian mink may either recover or live for years with AD (Porter et al., 1980). 
Clinically, AD is characterized by gradual loss of weight, anemia, and uremia 
ulceration of oral mucosa and in rare occasions, nervous signs. The gross lesions include 
emaciation (Fig. 1. 1), hepatomegaly with small pinpoint pale foci scattered through the 
parenchyma, generalized lymphadenopathy with the spleen and lymph nodes two to four 
times their normal size, nephritis characterized by enlarged kidneys with widespread 
petechiae early in the course and by shrunken pale kidneys with cortical cysts during the 
later stages. Histologically, there is widespread proliferation and infiltration of plasma 
cells in practically all organs (Obel, 1959; Henson et al., 1992). These cells are mostly of 
the preivascular type early in the disease. The plasmacytosis leads to a marked 
hypergamma-globulinemia, which may exceed 50% of the total serum proteins. The 
glomeruli in affected kidneys are relatively a vascularized and contain a large amount of 
slightly granular, eosinophilic material. Mononuclear cells proliferate in the liver. In the 
early stages of the disease the all infiltrate is a mixed population of lymphocytes, 
histiocytes, and immature plasma cells. Later, mature and immature plasma cells 
dominate. In addition, there is a progressive renal disease characterized by mesangial 
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proliferative glomerulonephritis and severe interstitial nephritis comparable to that seen 
in human diseases such as systemic lupus erythematosus (Bloom et al., 1994). Additional 
symptoms include decreased fertility, abortion, acute pneumonia in kits, and chronic, 
persistent infections, all of which severely impact the profitability of mink farming 
(Porter et al., 1980). 
ADV Genome Structure, Protein, and Replication 
The organization of the 4,748-nucleotide ADV DNA genome (Bloom et al., 1990) 
resembles other autonomous parvoviruses in that there are major right and left open 
reading frames, and palindromic structures at both 3' and 5' termini (Bloom et al., 1990). 
The nucleic acid consists of a 4.8 kilo base single-stranded DNA (Mayer et al., 1983). 
The size of AD virus particles ranges from 22 to 25 nm. Each 22 to 25 nm particle 
contains only a single strand of DNA, the minus sense strand in> 90% of virions (Bloom 
et al., 1993). The virus is non-enveloped and has cubic symmetry and contains 32 
capsomeres. The density of the complete virus in cesium chloride (CsCl) is 1.39 to 1.42 
g/cm3 (Berns and Labow, 1987). 
Permissive replication of the non-pathogenic strain of virus, ADV-O (ADV-Utah 
1 by Gorham) in Crandell feline kidney (CRFK) cells resembles that of other 
parvoviruses (Bloom et al., 1990). After adsorption and uncoating, the single-stranded 
genome is converted into a variety of double-stranded replicative forms, from which the 
single-stranded genomes are derived. The number of DNA molecules in an infected cell 
is large, :::: 105 copies of both duplex replicative forms and single-stranded virion 
molecules per infected cell (Bloom et al., 1985; Alexandersen and Bloom, 1987). 
During the infectious cycle, four viral mRNAs (Rl, R2, R2', and RX) are 
synthesized from a promoter at map unit 4 (P4) and one mRNA (R3) from another 
promoter at map unit 36 (P36) (Alexandersen et al., 1988a). Rl, R2, and R3 terminate 
with a polyadenylation signal located at map unit 92, whereas R2' and RX utilize a 
termination signal at map unit 53. Cells permissively infected with ADV contain> 105 
copies of viral mRNA (Alexandersen et al., 1988b), and all the RNA species are 
complementary to single-stranded virion DNA. 
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The 2.8-kb R3 mRNA codes for the two capsid proteins, VP-1 (P85) and VP-2 
(P75), which arise by alternate initiation on the same mRNA (Alexandersen et al., 1988a; 
Christensen et al., 1993). VP-2 coding sequences are fully contained within the large 
right open reading frame, whereas VP-1 contains additional sequences joined to the 
amino end of VP-2 (Bloom et al., 1982; Alexandersen et al., 1988a; Christensen et al., 
1993). 
The mRNAs specified by P4 encode at least two nonstructural (NS) proteins 
(Bloom et al., 1982; Alexandersen et al., 1988a; Christensen et al., 1993), analogous to 
those found for minute virus of mice (MVM) and other parvoviruses. The ADV NS 
proteins are derived by complex, differential mRNA splicing of the major left open 
reading frame and smaller open reading frames in the mid-genomic region (Alexandersen 
et al., 1988a). All of the ADV NS proteins share a common amino terminal portion of 59 
residues, but there are unique regions for each NS protein as well. 
The large 4.3-kb mRNA, which contains almost the entire left open reading 
frame, codes for the 71-kDA (Bloom et al., 1983) major nonstructural protein 1 (NSl), a 
protein with pleiotropic function (Bloom et al., 1983; Christensen et al., 1993). 
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Parvoviral NS 1 is required for viral genomic replication and excision of single-stranded 
virion DNA from double-stranded replicative form DNA (Bloom et al., 1983; Rhode, 
1985, 1989; Christensen et al., 1993). In addition, NSl functions as a transcriptional 
regulator by trans-activating the P36 promoter and thus controlling the level of capsid 
protein mRNA (Ahn et al., 1989; Doerig et al., 1990; Hanson and Rhode 1962). NSl can 
also regulate its own transcription and may be involved in influencing the level of 
cytopathology induced by the virus (Labow et al., 1986; Berns and Labow, 1987; Ozawa 
et al., 1988; Legrand et al., 1993). 
Both the 2.8-kb R2 and 0.85-kb R2' mRNAs code for a smaller nonstructural 
protein 2 (NS2), -13.4 kDa in size (Cotmore and Tattersall, 1986; Alexandersen et al., 
1988a). The difference between R2 and R2' is that R2' terminates at a polyadenylation 
site at map unit 53, whereas R2 continues with a long 3' noncoding region that ends at the 
map unit 92 polyadenylation signal (Alexandersen et al., 1988b). The function of NS2 is 
not well understood, but it is required for efficient replication in a cell-type specific 
fashion (Brandenburger et al., 1990; Brownstein et al., 1992). It should be noted that the 
ADV R2 transcript also contains all the required coding sequences necessary for 
production of the capsid proteins, and in fact, a recombinant baculovirus expressing this 
mRNA direct will synthesis of small amounts of capsid proteins in addition to NS2 
(Christensen et al., 1993). 
The 1.1-kb RX mRNA may specify an additional nonstructural protein, 
tentatively designated as NS3 (Alexandersen et al., 1988b). A baculovirus containing 
this gene directs expression of an appropriate sized protein in insect cells (Christensen et 
al., 1993). NS3 has not been found for the other autonomous parvoviruses; however, 
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MVM has several different isoforrns of NS2. Thus, if NS3 is a real viral gene product, 
it may subserve the function of NS2 isoforms. Preliminary sequence analysis of 
additional strains of ADV suggests that the requisite splicing junction for RX may be 
lacking from the RNA Rl in some in vivo derived ADV strains. 
At the peak of replication, viral antigen is detected in cells associated with the 
distribution of macrophages in lymphoid organs and Kuffer's cells liver, and the location 
of viral antigen is cytoplasmic, suggesting that the virus is sequestered in phagocytic cells 
(Porter et al., 1969). At later times in the infection, virus levels decrease significantly, 
but complete viral clearance is infrequently observed (Larsen and Porter, 1975). Because 
ADV occurs in infectious immune complexes and is probably sequestered in phagocytic 
cells, the simple identification of virus, virion proteins, and DNA is not adequate proof 
that actual replication is occurring in a particular site. Therefore, it is necessary to use 
reagents that mark obligate intermediates of active viral gene expression (e.g., replicative 
from DNA, mRNA, and nonstructural proteins; Alexandersen et al., 1988a). 
Virion DNA is widespread in lymphoid and phagocytic organs. It is apparently a 
sequestered in cells of the reticuloendothelial system, including follicular dendritic cells 
(FDC) and macrophages (Kanno et al., 1992). This suggests that some virus might be 
bound as immune complexes to the FDC (Mori et al., 1991). Replicative from DNA and 
mRNA, the two obligate intermediates of de nova virus replication, are present at greatly 
reduced or restricted levels as compared to permissively infected mink kit lungs or cell 
culture (Alexandersen et al., 1988a). Nevertheless, evidence suggests that a small 
percentage of macrophages support viral replication and gene expression (Mori et al., 
1991) and that FDC and lymphoblasts may also be targets. Importantly, the number of 
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cells sequestering virion DNA is at least 10 times greater than the number containing 
ADV RNA, suggesting that the number of cells containing ADV support an active 
infection (Alexandersen et al., 1988a). 
At later times after infection, when the immune disorder is evident, the amount of 
virus is further reduced (Alexandersen et al., 1988a). Virion DNA remains detectable in 
the sequestered pattern observed at earlier times, but only in cells in lymphoid tissues that 
appear to be macrophages (Mori et al., 1991). Furthermore, throughout the course of 
disease, other organs such as nucleated blood cells, bone marrow, liver, kidney, and 
spleen also contain viral sequences (Alexandersen et al., 1988a). 
AD of Newborn Mink 
Less than 2 weeks after neonatal infection, mink kits can develop an acute 
interstitial pneumonia (Alexanderson, 1986). Within a few days, they succumb to a fatal 
respiratory distress syndrome characterized by parenchymal hemorrhage, extensive 
atelectasis, and hyaline membrane formation. With highly virulent strains, incidence and 
mortality are >90%. In contrast, the incidence of disease is between 50-70% and 
mortality is 30-50% with low-virulence strains. Survivors develop typical lesions of the 
classical chronic adult form of AD regardless of the infecting strain (Alexanderson et al., 
1994). 
In AD of newborn mink, there is no question of where the virus is replicating. 
The disease in kits is characterized by ADV infection of type II alveolar cells, with capsid 
and nonstructural proteins readily demonstrable in the infected cells. Approximately 
10% of the type II cells are actually infected in these animals (Alexanderson et al., 1987). 
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Infection of these cells, which produce pulmonary surfactant, presumably leads to a 
functional surfactant deficiency and to the fatal severe respiratory distress. Although the 
main target in kits is the type II alveolar cell, virus replication occurs in cells of other 
tissues, such as in the lymph node, spleen, kidney (Alexanderson et al., 1987; 
Alexanderson, 1990). In situ and Southern blot hybridization studies indicate that the 
levels of replicative intermediates in the infected alveolar type II cells are very high, on a 
par with those found in cell culture (::::::105 copies per infection cell; Alexanderson et al., 
1987). This apparently unique susceptibility of the type II cells in the newborn period 
may be due to several factors. First, during the immediate postnatal period, type II 
pneumocytes are rapidly dividing and rapidly dividing cells are, in general, more 
susceptible to parvoviruses. In addition, newborn mink kits are not able to mount as 
rapid an immune response as adults (Alexanderson, 1986; Alexanderson et al., 1994). 
Pathogenesis of Aleutian Mink Disease 
Most pathogenesis studies have involved experimentally induced infections in 
which uninfected mink are exposed to spleen homogenates from other infected mink, 
either intraperitoneally or intranasally. Under these conditions, not only are viral 
particles introduced, but also antibodies that may enhance uptake of the virus into cells 
and other inflammatory mediators are also inoculated with virus. It has been assumed 
that the virus is naturally transmitted via a mucosa! route where it penetrates the 
epithelium of the gastrointestinal or respiratory systems. The incubation period in natural 
infections appears to be longer than that in experimentally-induced infections, indicating 
possible fundamental differences in the pathogenesis of disease between natural and 
13 
experimentally-induced infection. In experimentally infected mink, a three to ten day 
interval may exist between appearance of viral DNA in blood leukocytes, as determined 
by the polymerase chain reaction (PCR), and appearance of antibody. When mink are 
first infected with the virus, there are large amounts (107 - 108) of virus particles in the 
blood before antibody appears. With the appearance of antibody, the virus titer in the 
blood decreases. After a few weeks, the virus either disappears or can be detected in only 
small quantities in the blood. In demi mink, there is a good linear relationship between 
the amount of virus in blood after 6 months of infection and lesions. In dark mink, there 
is not a linear relationship because smaller amounts of virus in blood can be associated 
with severe lesions. 
A simplified scheme for a grand unified theory of AD pathogenesis might be 
portrayed as follows: An initial round of AD virus infection occurs in antigen presenting 
cells, perhaps in macrophages, follicular dendritic cells (FDC), or an as yet in an 
unrecognized primary target cell (such as renal tubular cells), providing an initial burst of 
virus that stimulates the immune system to produce anti-ADV antibody. Further ADV 
antigen stimulation leads to preferential induction of Th2 helper T-cell types, and the 
creation of a Th2 cytokine-laden milieu in lymphoid follicles. The FDCs present ADV 
antigens to B cells, programming them for differentiation into anti-ADV antibody plasma 
cells. In a subpopulation of macrophages, a restricted, antibody-dependent infection 
(ADI) leads to the production of the cytokine, IL-6. IL-6 mediates a polyclonal 
stimulation of the programmed B cells and synthesis of large amounts of antiviral 
antibody. The stimulated B cells also release IL-6 and stimulate other B cells to follow 
the same path. In the face of the persistent infection, the antiviral antibody reacts with 
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virus, creating a chronic load of virus-containing immune complexes. This sustains a 
repeating cycle of virus loading onto FDC and macrophages, programming of anti-ADV 
B-cells and production of IL-6. The self-reinforcing circuit that results impairs normal 
regulatory mechanisms, leading to hypergammaglobulinemia and plasmacytosis. 
Deposition of immune complexes in glomeruli and arteries results in immune complex 
disease. Virus also infects cells in the renal tubular epithelium, and the infected cells 
become a target for T cells and other lymphocytes primed to react against infected cells, 
leading to interstitial nephritis. 
Transforming Growth Factor-/3 (TGF-/3) 
The initial identification of transforming growth factor (TGF-~), was based on its 
ability to reversibly induce phenotypic transformation of elect fibroblast cell lines 
(Derynck, 1992). Although transforming growth factor (TGF-~) was originally named 
for its ability to reversibly cause a phenotypic transformation of rat fibroblasts (Moses et 
al., 1981), numerous bioassays describing cartilage inducing factor (Seyedin et al., 1985), 
glioblastoma immunosuppressive factor, myoblast differentiation inhibition factor 
(Fiorini et al., 1986), and epithelial growth inhibitor (Holley et al., 1980) were found to 
be measuring the same TGF-~ protein. 
The initial detection of TGF-~ activity in a transformation assay suggested a role 
for TGF-~ in malignant transformation and tumor development. It is now well 
established that the activities of TGF-~ are by no means restricted to tumor cells, but that 
TGF-~ exerts a multiplicity of biologic activities on most cells, both normal and 
transformed, and regulates many cell physiologic processes. The biologic response to 
TGF-~ is complex and depends not only on the cell type but on the physiologic 
conditions. Furthermore, TGF-~ also plays an important role in the control of the 
immune response and wound healing and in the development of various tissue and 
organs. 
Genomic Organization of the TGF-/J1 Gene 
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Multiple species of TGF-~ which are encoded by different genes have been 
identified. TGF-W s are disulfide-linked polypeptide dimers of molecular mass 25 kDa. 
Each mature chain is 112 amino acids in length and is derived from a larger precursor. In 
mammalian genomes, at least three genes encode TGF-~ precursors (TGF-~ 1• ~ 2, and ~3). 
TGF-~ 1• ~ 2, and ~3 are each coded by a single gene located on separate chromosomes, m 
humans on 19q13.1, lq41, and 14q23 (Fujii et al., 1986; Barton et al., 1988). 
The human TGF-~ 1 precursor is encoded by seven exons. The similarity of their 
seven exon structures and the high degree of conservation of their exon/ intron borders 
indicate that these genes are derived from a common ancestor (Derynck et al., 1987). 
TGF-~s have unique 5' long untranslated regions (UTR). For TGF-~ 1, there is a region of 
841 untranslated base pairs and 50 untranslated base pairs in 7 exon. In contrast to TGF-
~2 and ~3 promoters, ~1 does not have a traditional "TAT A" sequence. Instead, just 
upstream of the first transcriptional start site, the TGF-~ 1 promoter has a very GC-rich 
region with several Spl binding sites. 
The TGF-~ 1 precursor is 390 amino acid. All the potential N-linked glycosylation 
sites lie outside the bioactive domain. The TGF-'31 precursor contains an amino-terminal 
hydrophobic signal sequence (aa 1-23) for translocation to the endoplasmic reticulum to 
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undergo exocytosis. The pro-region (aa 24-278) guides the correct folding and 
disulfide bonding of the bioactive domain during TGF-f3 synthesis (Gray and Mason, 
1990). The bioactive domain (aa 279-390) is the carboxyl-terminus of the precursor, 
preceded by a sequence of four basic amino acids, which form the cleavage site. 
Intracellular proteolytic cleavage probably occurs by furin peptidase after dimerization of 
the precursors (Dubois et al., 1995). Active TGF-f3 is usually a homodimer but naturally 
occurring TGF-f31, f32 and f33 heterodimers can also be found. 
The amino acid sequences of all three mature TGF-f3 isoforms are strictly 
conserved; there is 98-100% identity between chicken and human. The evolutionary 
pressure to retain such a degree of conservation suggests that the functions of each 
isoform are critical. The degree of homology of the bioactive domain between the three 
human isoforms ranges from 70-80%, with much greater sequence divergence in the 
precursor region. 
Structure ofTGF-/3 
Since the original construction of the cDNA clone of TGF-f3, extensive protein 
characterization and cDNA analysis have revealed a large group of structurally related 
secreted factors. In addition to being multifunctional, TGF-f3 is a member of a large 
family of factors with widely diverse activities. The TGF-f3 superfamily was first 
recognized in the late 1980s (Sporn et al., 1987). Since then, the superfamily has grown 
to more than 25 members, with some of the molecules being grouped into four distinct 
subfamilies owing to highly related structures (Roberts and Sporn, 1990). Each precursor 
contains an N-terminal signal peptide, a long prosegment, also called the "latency-
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associated polypeptide" (LAP) and a 112-amino-acid C-terminal polypeptide that 
constitutes the mature TGF-13 monomer. This monomer is cleaved from the remaining 
precursor segment following a tetrabasic peptide. 
The active form of TGF-13 is a hydrophobic, disulfide-linked dimer of the C-
terminal segment of the pre-pro-TGF-13 (Derynck et al., 1985; Cheifetz et al., 1987). The 
three TGF-13 species, with a sequence identity of 70-80% (Derynck et al., 1988), are thus 
generated as homodimers of two identical C-terminal polypeptides, although 
heterodimers consisting of TGF-131 and TGF-132 have also been isolated (Cheifetz et al., 
1987). The biologic relevance of the heterodimeric species is unclear, especially as they 
presumably correspond to only minor species. The 112-amino-acid mature TGF-13 
polypeptide includes nine conserved cysteines, eight of which are paired. All cysteines 
form intra-chain disulfide bonds, with the exception of one intermolecular cysteine bridge 
responsible for dimerization. Three-dimensional structure analysis has revealed an 
extended butterfly-like structure of the TGF-132 homodimer, rather than the compact 
globular structure frequently seen in highly stable and temperature and protease resistant 
growth factors (Daopin et al., 1992). The sequence between the fifth and sixth cysteine, 
which has the most sequence divergence among the different TGF-13 isoforms and the 
other members of the TGF-13 superfamily, is exposed at the surface of this molecule and 
plays an important role in the determination of the specificity of ligand-receptor 
recognition. 
The prosegments of the three TGF-13 precursors show a sequence identity of only 
25-35%. Nevertheless, some structural elements are strongly conserved, suggesting 
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critical roles either in the function or in the folding of this prosegment. Among these 
conserved features are three cysteine residues and two N-glycosylation sites.' Two of the 
three cysteines are involved in intermolecular disulfide bridge formation (Miyazono et al., 
1988; Derynck et al., 1998). Finally, a hydrophobic stretch of amino acids closely 
following the signal peptide is conserved as well and may be involved in the folding of 
the precursor segment (Lopez et al., 1992). 
Biochemical characterization has shown that TGF-B is normally secreted as a 
protein complex, consisting of the mature TGF-B homodimer and two prosegments, 
which interact non-covalently with the mature dimer. The participation of mature TGF-
B in this complex prevents it from interacting with the TGF-B receptors, thus rendering 
this complex inactive or latent. Based on antibody recognition researches, it is likely that 
this interaction of TGF-B with the much larger prosegments leaves little of the mature 
TGF-B exposed at the surface of this complex (Wakefield et al., 1988). 
The expression of the three TGF-B isoforms is differentially regulated. Thus, 
different inducers or exogenous agents have distinct effects on the secretion of individual 
TGF-B species. This differential regulation of expression is largely due to a characteristic 
and independent pattern of transcriptional regulation of the three TGF-B species, which is 
in turn regulated by distinct control elements in the promoters of the genes (Roberts et al., 
1991). In addition, all three TGF-B isoforms have long 5' untranslated sequences which 
most likely play an isoform specific role in the regulation of translation efficiency 
(Derynck et al., 1985; Kim et al., 1992). 
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Receptors and the Cytokine Network 
Low numbers of high-affinity receptors for TGF-~ are found on most normal 
resting and transformed mammalian cells. The two major TGF-~ receptors, types I and 
II (TGF~RI, 53 kDa, and TGF~RII, 70-80 kDa), are both serine/ threonine kinases used 
by many of the mitogens, whose action TGF-~ opposes (Derynck, 1994; Massague et al., 
1994). Each has a small extracellular region, a single transmembrane domain, and an 
intracytoplamic serine/ theronine kinase domain. The large numbers of cysteines in the 
extracellular domain with a cluster of three just upstream of the transmembrane are 
characteristic of all signaling receptors of the TGF-~ superfamily. Almost all cells, 
regardless of their origin, express TGF-~ receptors and bind TGF-~ with high affinity. 
Signaling has been shown to require the formation of a trimeric complex consisting of 
both TGF-~ receptors I and II. The type III receptor, a transmembrane proteoglycan, has 
a short, highly conserved cytoplasmic domain without an apparent signaling motif 
(Lopez-Casillas et al., 1993). Other binding proteins for TGF-~ include 
cxrmacroglobulin, fibronectin and ~-amyloid precursor. 
The cloned type I receptor has a high-affinity binding for TGF-~ 1 and TGF-~ 3 but 
not TGF-~ 2 (Lin et al., 1992). The kinase domain of TGF~RII is flanked by a spacer 
between the domain and the transmembrane region and a carboxy-terminal tail. The 
kinase domains of the associated type II receptors of the superfamily show less than 40% 
amino acid sequence identity, suggesting that this divergence might be involved in 
conferring some signaling specificity. 
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In addition, type I receptors have a much shorter carboxyl-terminal tail and the 
extracellular domain has a distinct clustering of five cysteines. The type II receptors can 
bind ligand directly from the medium, while type I receptors cannot (Massague et al., 
1994 ). Type I receptors recognize ligand that is bound to type II receptors, with which 
they form a complex, probably a heterotetramer. If distinct heterodimers have different 
functional specificities, this could provide another way of expanding the regulatory 
flexibility of TGF-~ superfamily. 
The role of TGF-~ in immune surveillance and immunotherapy must be 
conceptualized in the context of its role as a cytokine, participating in the cytokine 
network. This integrated network includes contribution and immunity. The outcome of 
an immune response is the result of the balance between synergy and antagonism of 
several cytokines, and dysregulation at any level can contribute to disease pathogenesis. 
Like other cytokines, TGF-~ is highly potent, acting on cell surface receptors at 
femtomolar concentrations (10- 15M). Since different cell types possess receptors for the 
same cytokine, TGF-~ like other individual cytokines, may have multiple effects on the 
growth, differentiation and function of many cell types. 
TGF-/3 in the Immune System 
There is considerable evidence for an immunomodulatory role of TGF-~ and its 
function as a potent differentiation modulating and immunosuppressive agent (Letterio 
and Roberts, 1998). In culture most cells of the immune system, such as lymphocytes, 
monocytes and dendritic cells, synthesize TGF-~ that is almost exclusively TGF-~1- The 
TGF-~ released by these cells is mostly not active, suggesting that activation of the latent 
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complex is required before TGF-B can exert its function. The target cells are not only 
the different leukocytye cell types, but also various other cell types in the immediate 
tissue environment, such as endothelial cells or tumor cells, indicative of autocrine and 
paracrine actions. Once activated, TGF-B exerts a variety of activities on proliferation, 
differentiation and function of various cell types of the immune system. 
TGF-B often inhibits cell proliferation, as has been shown for T lymphocytes, B 
lymphocytes, thymocytes, natural killer (NK) cells, large granular lymphocytes, and 
lymphocyte activated killer (LAK) cells (Rook et al., 1986; Kehrl et al., 1986a; Wahl et 
al., 1988). Furthermore, the response may depend strongly on the state of differentiation 
of the cell and on the context of cytokines to which the cells are exposed. Accordingly, 
these different types of immune cells all have TGF-B receptors. 
One of the cell populations, which is strongly regulated by TGF-B are the T 
lymphocytes. Activated T cells secrete TGF-B and exogenous TGF-B inhibits 
interleukin-2-dependent proliferation (Kehr! et al., 1986b ). In addition, TGF-B also 
inhibits the secretion of a variety of cytokines and in this way inhibits the effector 
function of the activated cells. Thus, TGF-B inhibits the effects and/ or the production of 
interferon-y (IFN-y), tumor necrosis factor (TNF) -a and-Band interleukins-I, -2, -3, and 
expression of interleukin-2 receptor (Ohta et al., 1987; Letterio and Roberts, 1998). The 
endogenous synthesis of the TGF-B and the increased cytokine production in TGF-B1-
deficient mice strongly suggests that cytokine production is under autocrine control of 
TGF-P (Shull et al., 1992). The inhibition of cytokine production and the anti-
proliferative effect are presumably the major effector functions in TGF-B-induced 
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immunosuppression, especially as it relates to the cytolytic activities of the immune 
system. Accordingly, TGF-B has been shown to be a strong inhibitor of the generation 
and cytolytic activity of cytotoxic T cells, NK cells and LAK cells, and to suppress the 
natural and lymphokine-activated killing by large granular lymphocytes (Roberts and 
Sporn, 1990). 
Other evidence for the strong immunosuppressive effect of TGF-B on 
lymphocytes comes from the observation that TGF-B downregulates interferon-y-induced 
major histocompatibility complex (MHC) class II antigen expression by both lymphoid 
and non-lymphoid cells (Czarniecki et al., 1988). In contrast to the inhibitory effects of 
TGF-B on T lymphocytes, TGF-B also enhances the growth of immature lymphocytes 
and inhibits T-cell apoptosis, thus allowing expansion of the effector population (Rich et 
al., 1996). 
Finally, TGF-B may play an important regulatory role in differentiation of T cells. 
TGF-B can induce the expression of CD8 and can synergize with TNF-a to favor the 
development of cells expressing CD8. Conversely, TGF-B inhibits later stages of 
differentiation and thus inhibits the generation of CD4+/ CD8+ cells (Suda and Zlotnik, 
1992; Takahama et al., 1994). Whereas TGF-B was initially shown to strongly promote 
the generation of Th 1 cells (Schmitt et al., 1994 ), a subset of helper T cells with a 
characteristic cytokine secretion pattern, TGF-B has recently been more clearly 
implicated as a positive regulator of differentiation of Th2 cells and a suppressor of 
differentiation of Thl cells (Schmitt et al., 1994). 
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TGF-~ also plays an important role in the function of B cells. The expression 
of TGF-~ is regulated and is likely to depend on the differentiation state of these cells. 
For example, activation of B cells with Staphylococcus aureus Cowan mitogen strongly 
increases TGF-~ 1 secretion without a major effect on mRNA levels, white 
lipopolysaccharide (LPS) stimulates the activation of TGF-~, which is required for LPS-
induced immunoglobulin G (lgG) secretion by B cells (Kehrl et al., 1986a; Snapper et al., 
1993). Furthermore, activation of the B cells by binding of an anti-IgM antibody to cell 
surface IgM also induces the secretion of active TGF-~ 1 (Warner et al., 1992). The 
stimulation of TGF-~ expression by B cells most likely plays an important autocrine role 
in B cell function, as TGF-~ has a potent ability to inhibit cell (Gordon et al., 1994). 
TGF-~ also regulates B-cell differentiation and immunoglobulin expression. Indeed, 
TGF-~ suppresses the expression by activated B lymphocytes of membrane 
immunoglobulin and decreases secretion of immunoglobulins of different classes (Kehrl 
et al., 1986b ). However, antibodies to TGF-~ decrease the secretion of various 
immunoglobulin classes without affecting IgM secretion, suggesting that low levels of 
TGF-~ may regulate and be required for immunoglobulin secretion (Snapper et al., 
1993). Furthermore, the presence of TGF-~ promotes isotype switching of 
immunoglobulins, likely associated with differential transcriptional regulation (Coffman 
et al., 1989). 
TGF-~ also plays an important role in the physiology and functional regulation of 
monocytes and macrophages. As with cells of many other hematopoietic cell lineages, 
monocytes and macrophages secrete TGF-~ 1 in a highly regulated fashion. In addition, 
24 
the activation of the latent TGF-~ complex is also highly regulated. For example, 
treatment of monocytes with LPS or macrophages with concanavalin A results in a 
drastically increased activation of TGF-~ without changes in mRNA levels (Grotendorst 
et al., 1989). In addition, TGF-~ 1 synthesis by monocytes is strongly induced by TGF-
~ itself (Wahl et al., 1989). Thus, TGF-~ can induce or inhibit cell proliferation 
depending on the physiologic context (Fan et al., 1992). Low concentrations of TGF-
~ induce a chemotactic response, which may be important for the recruitment of these 
cells at sites of inflammation, in activating cells to secrete a variety of cytokines which 
may play a role in the inflammatory response and often associated angiogenesis, and to 
increase their expression of adhesion receptors (Wahl et al., 1993). The important role of 
TGF-~ is further illustrated by the inflammatory response to subcutaneous injection of 
TGF-~, which elicits a sequence of events, including inflammatory cell recruitment, 
fibroblast accumulation and vascular growth, which is similar to the normal inflammatory 
response to injury (Roberts et al., 1986). It is thus conceivable that the release of TGF-
~ by activated degranulating platelets results in an influx of monocytes, which 
accompanies the initiation of the inflammation, and of fibroblasts, and may explain the 
appearance of fibroblasts at the site of injury (Postlethwaite et al., 1987). Following 
recruitment of monocytes, the TGF-~ at the site of inflammation then presumably 
activates monocytes to induce secretion of growth factors and inflammatory mediators, 
that are likely to amplify further the inflammatory response and to initiate the repair 
processes at the site of injury. 
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In contrast to these proinflammatory activities, TGF-~ also inhibits a variety of 
activities of macrophages, which result in a suppression of macrophage function and are 
likely to contribute to a resolution of the inflammatory response. This drastic change in 
cell response may be causally related to decreased expression of cell surface TGF-
~ receptors as cells mature. Thus, TGF-~ can inhibit the production of cytokines, 
including interferon-y and increase the expression of the interleukin-I receptor antagonist 
by macrophages (Fargeas et al., 1992; Bauvois et al., 1996). Finally, TGF-~ also strongly 
inhibits the expression of nitric oxide synthetase and in this way is likely to downregulate 
the antimicrobial and tumoricidal response (Bogdan and Nathan, 1993). The pro-
inflammatory activity of TGF-~ on monocytes and the subsequent deactivating activity 
on macrophages clearly illustrate the highly coordinated role of TGF-~ in the complex 
response to injury and its modulatory role at the site of repair and inflammation. 
Furthermore, TGF-~ also inhibits differentiation of cytotoxic CD8+ T cells, which are 
instrumental in eliminating infected cells (Barra! et al., 1995). 
Endogenous TGF-~ may also plays a regulatory role in limiting immune function 
in vivo and in some pathologic dysfunctions of the immune system. Some new insights 
into the role of TGF-~ in immune suppression and the mechanism of TGF-~ presentation 
have been revealed through studies of MRUl pr mice, which develop systemic 
autoimmune disease resembling human systemic lupus erythematosus, probably resulting 
in part from defective apoptosis (Steinberg, 1994). These mice have high levels of 
plasma TGF-~ 1 bound to IgG antibodies. The complex potently suppresses CD8+ 
cytotoxic T-lymphocyte responses in the presence of macrophages (Caver et al., 1996; 
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Stach and Rowley, 1993). Binding to IgG could restrict or target the activity of TGF-
p to antigenic sites where it could play an important role in suppression of autoimmune 
disease (Stach and Rowley, 1993). Furthermore, the IgG-bound TGF-P complexes could 
increase the susceptibility to bacterial infection and increase defects in 
polymorphonuclear leukocyte function (Caver et al., 1996). Finally, TGF-P bound to IgG 
results in a considerably higher (10-500-fold) activity than free TGF-P, suggesting that 
this recently discovered form of delivery of TGF-P results in an efficient targeting to 
specific receptors (Caver et al., 1996). 
Perhaps mice in which the TGF-B.1 gene is functionally inactivated by gene 
targeting provide the best illustration of the endogenous role of TGF-Pi in normal 
immune function and infiltration. Shortly after birth, these mice develop a multifocal 
mixed inflammatory disease with rapid and massive infiltration of lymphocytes and 
neutrophils in many tissues, and subsequently die (Shull et al., 1992). Thus, TGF-
P1 deficiency results in a severe pathology with dysfunction of the immune and 
inflammatory systems, which is accompanied by increased production of several cytokine 
mediators of inflammation, such as interferon-y, TNF-a and macrophage inflammatory 
protein-la (MIP-la) (Shull et al., 1992). These mice also show enhanced expression of 
MHC class I and II antigens, circulating antibodies to nuclear antigens, and pathogenic 
glomerular IgG deposits, thus resembling human autoimmune disease (Letterio and 
Roberts, 1998). The enhanced expression of MHC class II antigen in TGF-P 1 knockout 
mice is consistent with the ability of TGF-P to suppress its expression (Czarniecki et al., 
1988). 
In summary, there is ample evidence that TGF-B is major determinant of the 
immune and inflammatory response. Among the TGF-B isoforms, TGF-B 1 is probably 
the major effector molecule in most contexts, and TGF-B2 and TGF-B 3 may exert their 
major normal effects outside the immune system. 
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Fig. 1.1. An illustration of the postmortem lesions of AD on mink. The spleen, liver, and 
lymph are enlarged, and kidney have also enlarged, pale, yellow, and mottled. 
CHAPTER2 
AMELIO RA TING ALEUTIAN DISEASE IN MINK BY 
TREATMENT WITH HUMAN rTGF-~ 1 
Abstract 
Aleutian disease of mink (AD) is an immunopathological disorder of mink 
induced by persistent infection with AD virus. It is a naturally occurring viral infection 
caused by a parvovirus. 
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AD is serious problem in mink throughout the world. A major outbreak occurred 
in Summit and Morgan counties in Utah in 1994. This outbreak is still continuing and 
has resulted in some mink farms deciding to stop raising mink. 
The hypothesis to be tested in this research was that TGF-~ 1 treatment of mink 
will inhibit or ameliorate AD in mink. The study was conducted using four groups of 
mink. Each group included twenty-five mink and were treated at a different times 
relative to viral infection. 
At nine months, all the treated animals had low anti-ADV antibody titers, blood-
urea-nitrogen (BUN), interferon-gamma (IFN-y) and circulating-immune-complex (CIC) 
levels which were well within normal parameters. However, the non-treated, infected 
animals all died within four months after infection. These animals had high antibody 
titers and high BUN, IFN-y and CIC levels, suggesting that their kidneys were damaged 
by immune complex deposition, a hallmark of AD. Comparison of survival times 
between treated and non-treated animals demonstrated that treated animals survived 
almost twice as long as non-treated animals. Also, polymerase chain reaction (PCR) 
assay of lymph node tissue confirmed that non-treated animals had significant levels of 
virus whereas treated animals had none. 
These findings support the hypothesis that TGF-~ 1 supplementation does 
ameliorate the severity of AD in mink. 
Introduction 
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Aleutian disease (AD) is an immunopathological disorder of mink induced by 
persistent infection with Aleutian disease virus of mink (ADV) (Porter et al., 1980), a 
naturally occurring infection caused by a virus from the Parvoviridae family. The term 
"Aleutian disease" was coined because the recessive Aleutian genotype (gray coat color) 
of mink has a predilection for AD. Not only is this breed of mink characterized by 
extreme susceptibility to lethal, chronic AD, it also has a genetic defect called Chediak-
Higashi syndrome in which the lysosomes of the mink cells are very large and have some 
functional abnormalities, resulting in decreased lysosomal activity and/ or fusion of 
lysosomes with phagosomes in leukocytes, impairing phagocytosis (Padgett et al., 1967; 
Ward et al., 2000). 
The course and type of disease in ADV-infected mink is dependent on the age of 
the mink. In newborn kits, an acute AD presents fatal interstitial pneumonitis 
(Alexandersen, 1986). In adult mink, AD often progresses to a chronic, lethal infection 
characterized by proliferative glomerulonephritis and severe interstitial nephritis due to 
deposition of immune complexes consisting of antibody bound to ADV or to auto 
antigens (Porter et al., 1980). The adult mink show hair loss, poor quality fur, severe 
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emaciation (Fig. 2.1) and a diminished capacity to reproduce when infected with AD. 
The chronic infection also leads to immune complex disease. The mortality and 
morbidity of AD can reach up to 100%. These clinical signs are culminated by an early 
death in both adults and kits. Once the virus is present, complete herd infection is often 
imminent (Bloom, 1984). 
Attempts to immunize with attenuated or killed virus have failed; they only 
exacerbated the severity of the disease (Bloom et al., 1994). However, immunotherapy 
using immunosuppressive drugs such as levamisole and Isoprinosine, resulted in some 
slight amelioration of disease pathogenesis (Cheema et al., 1972). 
When ADV is first presented in to the mink immune system, both T helper 1 
(Thl) and T helper 2 (Th2) type of immune responses are activated. As the infection 
becomes chronic, a shift from the Thl to a dominant Th2 response is seen. The Th2 
predominance leads to the suppression of Thl type cytokines such as interleukin 12 (IL-
12) and interferon-y (IFN-y) (Bloom et al., 1994). This is critical due to the role these 
two cytokines play in the differentiation of T-cells and Thl responses. Thus, it would be 
interesting to determine if the immune response of mink exposed to ADV could be 
modulated to a cell-mediated response characterized by a Thl cytokine pattern. 
A cytokine of special interest for this research is transforming growth factor beta 
(TGF-~), which can modulate Thl and Th2 immune responses. Two families of 
"transforming growth factors" have been identified as TGF-a and ~- These are distinct 
peptides with very different spectra of biological activity. TGF-a is closely related to 
epidermal growth factor (EGF), whereas the family of TGF-~ proteins not only plays an 
important role in cell growth control and neoplasm development but also in inflammation 
45 
and immune regulation. TGF-~ proteins are multifunctional dimeric cytokines originally 
isolated from tumor cells, with molecular weights of 25kD and exerting pleiotropic 
effects on immune function. 
Among the important actions of TGF-~ proteins are the recruitment and activation 
of mononuclear cells, promotion of wound healing, fibrosis, angiogenesis, potent 
immunosuppressive action on numerous functions of T lymphocytes (Roberts and Sporn, 
1990) and modulation of cytokine production (Chantry et al., 1989). Inactivation of 
TGF-~ inhibits early hematopoietic growth and differentiation, alters B cell 
immunoglobulin (lg) production and class switching (Coffman et al., 1989). Inactivation 
of TGF-~ inhibits mast cell, thymocyte, B cell and T lymphocyte proliferation. 
In vitro studies have provided evidence that, in addition to inhibiting T 
lymphocyte proliferation, TGF-~ 1 inhibits the generation of cytotoxic T lymphocyte 
(CTL) activity, induction of IL-2-induced lymphokine-activated killer cell activity, 
generation of natural killer (NK) cell activity from murine NK cell bone marrow 
precursors (Migliorati et al., 1989), and IFN-y augmentation of NK cell activity mediated 
by human peripheral blood leukocytes. It is particularly plentiful in platelets, but it is 
also present in substantial quantities in mesenchymal cells, where it plays an important 
role in the remodeling of connective tissue that occurs during inflammation, bone re-
absorption, and wound healing. 
TGF-~ 1 produced by macrophages, T and B cells and other cells generally inhibits 
development and proliferation of cells in culture (Derynck and Choy, 1998). IL-2 or IL-5 
(Th2-type cytokines) may modify this inhibition while at the same time enhancing the 
production of IgA. 
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TGF-B1 may play an important regulatory role in differentiation of T cells. TGF-
B1 has been found to induce the expression of CDS+ on thymocytes suggesting that it has 
a differentiative function in addition to its anti-proliferative activity. For example, TGF-
B1 can induce expression of CDS+ protein and can act synergistically with TNF-a to favor 
development of cells expressing CDS+. Conversely, TGF-B1 inhibits later stages of 
differentiation and thus inhibits the generation of CD4+ and CDS+ cells (Suda and 
Ziotnik, 1992). Whereas TGF-B1 was initially shown to strongly promote the generation 
of Th 1 cells, a subset of helper T cells with a characteristic cytokine secretion pattern 
(Swain et al., 1991), it also has more recently been more implicated as a positive 
regulator of differentiation of Th2 cells and a suppressor of differentiation of Th 1 cells 
(Schmitt et al., 1994). Consequently, the microenvironment in which TGF-B1 interacts 
with varying concentrations of a mixture of other cytokines may determine the ultimate 
behavior of this multifunctional growth factor. 
Since TGF-B1 seems to modulate both Thl and Th2 responses, we wanted to 
investigate the role of this cytokine in ameliorating AD. The hypothesis to be tested in 
this research was that TGF-B1 treatment would inhibit or ameliorate AD in mink. The 
hypothesis was tested by evaluating the effects of TGF-B1 on the immune response of 
AD-infected animals, on the pathological features of disease, on certain physiological 
factors detectable in serum and by evaluating its effects on viral load. 
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Materials and Methods 
Virus 
The Utah I strain of ADV was obtained from Marshall Bloom (NIH, NIAID, 
Rocky Mountain Laboratories, Hamilton, MT). All animals exposed to virus were 
injected with virus intraperitoneally and received 5 X 105 fluorescent focusing units of 
ADV of mink. This inoculum was used to induce detectable disease within 2 to 5 months 
after virus exposure. 
Cells 
The macrophage cell line RAW 264.7 was obtained from American Type Culture 
Collection (Manassas, VA, USA). The cells were routinely passaged with in Dulbecco's 
modification of minimal essential medium (GIB CO Invitrogen Corporation, Grand 
Island, NY) containing 4000 mg/L glucose. The medium was supplemented with 4 mM 
L-glutamine (GIBCO Invitrogen Corporation), 0.1 mM sodium pyruvate (GIBCO 
Invitrogen Corporation), 0.15% sodium bicarbonate and 10% fetal bovine serum 
(Hyclone Laboratories, Logan, UT). 
Animals 
Unmated or non-parous one-year-old female mink weighing 600-1000 g were 
used. These mink were obtained from the Windy Peaks ranch facility (Franklin, ID). 
This facility has been free of AD for about 6 years as determined by serological testing 
and pathology results. Serum from each animal was tested by counter-immune 
electrophoresis (CEP) for the presence of antibody to AD. All animals received at the 
animal research facility were negative for AD by CEP testing. 
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Mink were fed once daily ad libitum diet (approximately 100 g) with a fish-based 
diet formulated for optimal growth, pelt quality and seasonal variations in nutritional 
needs by the Mink Farmer's Cooperative of Utah (Fig. A.1). 
Blood for analysis was obtained by toe clip, and when mink were sacrificed, they 
were euthanized by carbon monoxide inhalation in a sealed plexiglass chamber in an 
aerated room (Fig. A.2). 
Animals were held to up to 9 months. Signs of disease were measured monthly 
by analyzing serum samples using antibody, blood urea nitrogen, interferon gamma, and 
circulating immune complex assays. Confirmation of disease was measured by 
histopathological examination of kidney, liver, and spleen, and by detection of viral DNA 
in the mesenteric lymph nodes. In addition, animals were weighed monthly to determine 
weight loss or gain, weight loss being a symptom of AD. 
Study Design 
The study was designed to evaluate three different doses (200, 100 and 1 ng/kg) 
of recombinant human TGF-~ 1 (rhTGF-~ 1) and one dose (500 ng/kg) of TGF-~1 inhibitor 
(latency associated peptide [rhLAPTGF-~i] R&D Systems, Minneapolis, MN) at one of 
three different times of administration relative to virus exposure (Table A.1). Group 1 
received TGF-~ 1 two weeks prior to virus exposure, group 2 received treatment eighth 
post-virus exposure and group 3 received TGF-~ 1 2 weeks after virus exposure. Twenty-
five animals were assigned to each administration group, and within that group, five 
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animals were designated to receive one of three doses of rhTGF-j31, rhTGF-j31 inhibitor, 
or 0.1 % BSA in PSS (placebo). A separate group (group 4) of five animals ieceived 
TGF-131 at 200 ng/kg 2 weeks prior to virus exposure, again 8 h after virus exposure and 
then 2 weeks after virus exposure (Fig. A.3). 
Animals were administered drug or placebo intravenously via the inguinal vein 
and virus was injected intraperitoneally using a 1 :500 dilution of clarified spleen 
homogenate (approximately 1 X 105 fluorescent focus units). This inoculum was used to 
induce detectable disease or death within 2 to 5 months after virus exposure (Fig. A.4 ). 
Counter-immune Electrophoresis (CEP) 
The CEP tests (Aasted and Cohn, 1982) were performed according to the 
manufacturer's (United Vaccines, Inc. Madison, WI) instructions. Eight "units" of 
antigen per 10 µI were added to the appropriate wells and 10 µI of serum dilutions as well 
a positive control serum were added to wells in apposition to the antigen containing 
wells. Electrophoresis (55 volts for 60 min) was done using Tri-Barbital buffer (pH 8.6, 
Pall Gelman Sciences, Ann Arbor, Ml) as the wick buffer and 0.9% agarose (FMC 
corporation) as the matrix for the precipitation reaction (Fig. A.5). 
To visualize precipitin lines, the agarose-coated plate was illuminated bilaterally 
from below and viewed against a dark background. When results were obscured by 
hemolysis, the precipitin lines became more clearly visible by soaking the plates 15 min 
in 2% saline solution. Antibody titers were expressed as the last dilution of serum at 
which a precipitin line formed. 
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Blood Urea Nitrogen (BUN) 
Sigma Diagnostics Urea Nitrogen kit (Sigma, St. Louis, MO) was used for the 
quantitative, colorimetric determination of BUN in serum at 540 nm (Crocker, 1967). 
To prepare serum samples for analysis, the samples were treated with 3% cold 
trichloroacetic acid (Sigma) for 5 min at refrigerator temperature. The supernatant fluid 
used for the analysis was collected by centrifugation at 1500 X g for 10 min. Positive 
controls from the kit were used to generate a standard curve for calculating 
concentrations of nitrogen (mg/dl) detected in each sample. 
Interferon Gamma (IFN-y) Assay 
Interferon-y-stimulated macrophages produce large amounts of nitric oxide (NO) 
by cytosolic, NADPH-dependent inducible NO synthase (iNOS) (Kim and Son, 1996). 
Once cells have been stimulated by interferon-y, NO concentration can be determined by 
the amount of nitrite (NO2) accumulation in cell culture medium. Therefore, a nitric 
oxide production bioassay using the macrophage cell line RAW 264.7 was done to detect 
interferon-y mink sera (Kim and Son, 1996). 
RAW 264.7 cells were seeded in 96-well plates flat-bottomed (Corning Costar, 
NY) at a concentration of 1 x 105 cells/well. The were incubated 4-6 h and stimulated 
with mink serum samples or with 25 U/ml mouse interferon-y. All samples were diluted 
using a two-fold geometric dilution series. A row of wells was set aside for mink sera 
from normal, untreated mink to serve as a negative control. After 24 h of stimulation at 
37°C, the medium was collected from each well for measurement of nitrite accumulation. 
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Nitrite production was determined by adding 100 µl of Griess Reagent (1 part 
0.1 % naphthylethyleniamine dihydrochloride to 1 part 1 % sulfanilamide in 2% H3P04) to 
100 µl of supernatant fluid from stimulated RAW cells in a 96 well plate and mixing 
well. The absorbance was measured at 540 nm using a microplate reader. Mouse 
interferon-y concentration were plotted versus absorbance values to generate a standard 
curve from which NO concentration for each sample were extrapolated. 
Circulating Immune Complexes (CIC) Assay 
The BOHLMANN CIC-ClQ ELA Kit (ALPCO, Windham, NH) was used to 
quantitative determine the amount of circulating immune complexes (CIC) detectable in 
mink serum. CIC usually activate complement when formed in the host and normally are 
cleared by phagocytosis. The component of the complement system that binds these 
complexes is Clq. For this assay Clq was used to capture any immune complexes found 
in serum samples. CIC binding to Clq was detected using an alkaline phosphatase 
conjugated Protein A, which binds to the Fe region of IgG, the predominate antibody 
associated with immune complexes (Wehler et al., 1981; Endo et al., 1983). 
Dilutions of mink sera (beginning at 1 :50) kit standards and controls were 
incubated with human Clq pre-adsorbed onto microtiter wells for 1 h at room 
temperature. The kit protocol for detection of CIC was then followed. Absorbance at 
405 nm was read. CIC concentrations detected in various mink sera were calculated from 
standard curves generated using the positive controls provided in the kit. 
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TGF- /31 ELISA Development Assay 
Detection of TGF-~ 1 in serum samples was done using a DuoSet ELISA 
Development kit (R&D Systems, Minneapolis, MN) and following the instructions of the 
kit. 
Briefly, capture antibody was absorbed onto wells of a 96-well microplate and 
incubated overnight at room temperature. After washing, blocking buffer was added to 
each well and the plate incubated at room temperature for 1 h. Following three buffer 
rinses, diluted serum samples, standards in reagent diluent, and serum diluent, were 
added to appropriate wells in duplicate, and incubated 2 h at room temperature. 
Following the incubation and rinsing, detection antibody was added to each well and 
incubated two hours at room temperature. Following three rinses, streptavidin-
horseradish peroxidase conjugate (HRP) was added to each well, the plate sealed and 
incubated for 20 min at room temperature. After appropriate rinsing, substrate solution 
( 1: 1 mixture of H2O2 and tetramethylbenzidine) was put into each well and incubated for 
20 min at room temperature. After stopping the reactions with stop solution (2N H2SO4), 
absorbance was read using a microplate reader set to 450 nm and 540 nm. 
Mean absorbance for the standards plotted versus concentration of the standards 
to generate a standard curve and mean concentrations of TGF-~ 1 in each sample were 
derived from the standard curves. 
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Detection of Viral DNA 
Viral DNA was detected by polymerase chain reaction (PCR) amplification of 
viral DNA extracted from mesenteric lymph nodes of mink with subsquent visualization 
of the DNA gel electrophoresis. 
Approximately 0.25 g of mesenteric lymph node tissue was digested with 
proteinase K (Sigma). The DNA was then suspended in 500 µl of digestion buffer (0.01 
M Tris HCl, 0.001 M EDTA, pH 7.2 TE buffer), phenol-chloroform extracted, and 
ethanol precipitated using standard procedures. The sample DNA was stored at -80°C 
until amplified by PCR. 
Ten microliters of hydrated DNA (0.5-1.0 µg) was used for each PCR reaction. 
The reaction mix consisted of the following: 0.25 µM concentration of each primer, 0.2 
mM deoxynucleotide triphosphates, 50 mM KCl, IO mM Tri HCl (pH 8.8), 15 mM 
MgC]z, 0.2% Triton X-100, 2.5 units of Taq DNA polymerase (total volume of 100 µl). 
Primers were selected from the 5' end of the viral genome in a highly conserved non-
translated region (Bloom et al., 1988). Primer sequences were as follows, with 
nucleotide positions given in parentheses: upstream primer-GATGAGCAGAGGAGAC 
TGCA (224-243): downstream primer-AGTAACCTAAGCAACAGTGA (583- 602). 
The expected fragment size was 379 base pairs, representing nucleotides 224-602. For 
each set of reactions, positive and negative controls were used (Jackson et al., 1996). 
DNA for the positive controls consisted of 10 ng of the gel-purified amplified fragment. 
Negative controls consisted of approximately 1 µg of DNA isolated from blood cells of 
uninfected mink. Each cycle consisted of 1 min each at 95°C, 55°C, and 72°C. A total 
of thirty cycles was done, using a thermal cycler (Singblock TED, Ericomp, Inc., San 
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Diego, CA). After amplification, samples were separated on a 1.0% agarose gel in T AE 
buffer. Bands were visualized with ultraviolet light and photographed using Polaroid 
film. 
Histopathology Examinations 
Upon the death of each mink, either from AD or when sacrified the kidneys and 
liverwere removed and tissues from each were sectioned, fixed and then stained with 
hematoxylin and eosin. Typical pathological findings for AD included thickened 
mesangium in the glomeruli with homogenous eosinophilic material (membranous 
glomerulopathy), detection of multifocal infiltrates of plasma cells and lymphocytes in 
the interstitium of the kidney cortex (interstitial nephritis) and also in the medulla, 
multiple convoluted tubules containing eosinophilic material or granular casts, occasional 
mineralization basement membranes, and portal areas of the liver with varying numbers 
of infiltrated plasma cells and lymphocytes (hepatitis) randomly dispersed among the 
hepatocellular cords. Samples were coded and sent to a board certified pathologist (Utah 
State Veterinary Diagnostic Laboratory, Logan, UT), who examined the samples for the 
above-defined pathology; abnormalities were scored as mild ( + ), moderate ( ++ ), and 
severe ( +++ ). Samples with the pathology described above were considered positive for 
AD. 
Statistical Analysis 
Statistical significances were determined by analysis of variance and Student's t-




Infected, placebo treated animals all died of AD before the termination of the 
experiment (by 5 months into the experiment), with mean survival time of 149 ± 8 days. 
Mink treated with 1 ng/kg of TGF-~ 1 had survival times comparable to the infected, 
placebo control group as did mink treated with TGF-~ 1 inhibitor, regardless of the 
treatment regimen. Animals treated with TGF-~ 1 at 100 and 200 ng/kg had significantly 
(p ::; 0.05) prolonged mean survival times, again regardless of the treatment regimen. The 
average survival time for the four treatments groups at these dosages ranged from 200 ± 
33 days to 248 ± 17 days (Fig. 2.2). Survival increased of 10% to 60% (p ~ 0.05) were 
seen in the TGF-~ 1-treated groups. 
Body Weight 
Mink were weighed prior to any treatment and that weight was designated "pre-
exposure weight." The post-virus exposure weights represent the average weight of 
animals in each treatment group just prior to death or sacrifice. Mink which were 
untreated and not exposed to virus had significant weight increases relative to the 
infected, untreated (placebo) groups (Fig. 2.3, p < 0.01) and suffered from severe 
emaciation (Fig. 2.1 ). 
All TGF-~ 1-treated animals lost some weight compared to pre-exposure body 
weights (Fig. 2.3). However, those mink treated with TGF-~ 1 inhibitor placebo group 
suffered tremendous weight losses, consistent with typical AD pathology (Fig. 2.1 ). 
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Specific ADV Antibody Levels 
AD may be manifested at certain stages by exhibiting elevated serum' 
gammaglobulin levels. High titers of antibody (>512) are often associated with 
progressive chronic AD (Bloom et al., 1994). Therefore, serum was analyzed for ADV-
specific antibody as a marker for progression to chronic disease. 
Animals treated with TGF-f31 at 100 and 200 ng/kg had significantly lower anti-
ADV antibody titers than did the placebo-treated mink or animals treated with TGF-f31 
inhibitor (p ~ 0.05). The lowest average antibody titer occurred in the TGF-f31 group 2 in 
which treatment was given 8 h post virus inoculation (Fig. 2.4). The antibody titers for 
the placebo groups and the TGF-f31 inhibitor-treated groups exceeded the threshold 
(>512) commonly accepted as the point at which mink are likely progress to chronic AD 
often culminating in death (Bloom et al., 1994). 
Comparing the mean average CEP titers between the groups of TGF-f31-treated 
mink showed that those treated with TGF-f31 at 100 ng/kg in group 2 and those animals 
treated with TGF-f31 at 200 ng/kg in group 4 had significantly decreased mean CEP titers 
218 (p < 0.001) and 256 (p < 0.01), respectively, compared to controls group. 
Serum Levels of Urea Nitrogen 
Detectable levels of urea or other nitrogenous compounds in serum are sometimes 
indicative of damage to the kidneys, probably at the level of readsorption through the 
tubules. The BUN test used in this study provides results which often correlate with 
chronic renal failure due to distal tubule transport malfunction. 
Blood levels of nitrogenous compounds for all groups of mink were higher after 
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virus exposure when compared to the pre-virus exposure, pretreatment levels (Fig. 2.5). 
However, animals receiving treatment with TGF-~ 1 at 100 or 200 ng/kg had,' in general, 
significantly lower BUN levels after virus exposure compared to those levels in mink not 
treated with TGF-~ 1 or treated with TGF-~ 1-inhibitor (p < 0.05, Fig. 2.5). 
Serum Gamma Interferon (IFN-y) Activity 
Levels of interferon-y, a Thl type of cytokine, were assessed as a reflection of the 
effects of TGF-~ 1 treatment on Th 1 type responses using the method whereby mouse 
macrophage cells are stimulated in vitro with a serum sample putatively containing 
interferon-y and looking for a proportionate production of nitric oxide (Kim and Son, 
1996). 
Serum interferon-y levels were higher in all groups after virus exposure and/or 
treatment than in sera taken from mink prior to those events (Fig. 2.6). Levels of 
interferon-y were 1.2- to 3-fold lower in animals treated with TGF-~ 1 at 100 or 200 ng/kg 
than the levels in the placebo groups or in the TGF-~ 1 inhibitor mink. The levels in the 
mink treated with TGF-~ 1 at 1 ng/kg seemed to be midway between the levels detected in 
the other treatment groups described above. 
Circulating Immune Complex (CIC)Ttiters 
Circulating immune complexes (CIC) are formed by the interaction of antibodies 
with immunogenic antigens. Immune complexes with only a slight excess of antibody or 
antigen are soluble and activate complement and high levels of CIC are sometimes 
symptomatic of various autoimmune and other CIC-related diseases. 
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Since one of the hallmarks of AD pathology is the destruction of kidney tissue 
due to deposition of CIC in the kidney and subsequent antibody-mediated destruction of 
the basement membrane of kidney tubules, assays were done to determine CIC levels in 
mink using a commercially available kit. 
CIC levels were significantly lower in mink treated with TGF-~ 1 at 100 and 200 
ng/kg than those animals receiving TGF-~ 1 inhibitor or placebo-treated mink (Table 2.1, 
p ~ 0.05). Animals treated with TGF-~ 1 at 1 ng/kg seemed to have CIC levels midway 
between the groups discussed above. However, the CIC levels for the placebo-treated 
mink and mink treated with TGF-~ 1 at 1 ng/kg, and the TGF-~ 1 inhibitor were 
dramatically increased in comparison to levels detected in those same mink prior to virus 
exposure and/or treatment, suggesting chronic exposure to some agent(s) like ADV. 
Serum Levels of TGF-/31 
The effect of treatment with exogenous TGF-~ 1 on serum levels ofTGF-~ 1 in 
treated mink, is shown in Fig. 2.7. In general, TGF-~ 1 levels seemed to slightly increase 
in animals treated with TGF-~ 1 at 100 or 200 ng/kg compared to baseline levels. For 
mink treated with TGF-~ 1, the levels seemed to remain the same throughout the duration 
of the experiment. In the placebo groups and the groups of mink treated with TGF-~ 1 
inhibitor the levels of TGF-r31 appeared to drop compared to the levels found inthose 
groups prior to treatment and/ or exposure to virus (Fig. 2.7). 
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Virus DNA Levels 
To determine if virus was present in treated, infected animals, mesenteric lymph 
nodes of mink (Bloom et al., 1994) were harvested and assayed for viral DNA by PCR 
amplification and gel analysis from samples taken as soon after death as possible or 
immediately after sacrifice. 
Viral DNA was not detected in animals treated with TGF-~ 1 at 100 or 200 ng/kg 
with the exception of one animal treated with 200 ng/k:g in group 3 (Table 2.2). For the 
other groups of mink, viral DNA was present in the majority of animals. In mink treated 
with 1 ng/k:g TGF-~ 1, viral DNA could be detected in 60% of the animals. For the other 
groups, viral DNA was detected in four or five mink in each treatment regimen (Fig. 
B.1). 
Histopathological Examinations 
Typical pathological findings for AD included thickened mesangium in the 
glomeruli with homogenous eosinophilic material (membranous glomerulopathy), 
detection of multifocal infiltrates of plasma cells and lymphocytes in the interstitium of 
kidney cortex (interstitial nephritis) and also in the medulla, multiple convoluted tubules 
containing eosinophilic material or granular casts, occasional mineralization basement 
membranes, portal areas of the liver with varying numbers of infiltrated plasma cells and 
lymphocytes (hepatitis) randomly dispersed among the hepatocellular cords. 
With few exceptions, mink treated with TGF-~ 1 at 100 or 200 ng/kg tended not to 
have visible lesions in the kidneys and liver attributable to AD (Table 2.3). Most mink 
treated at the lowest dose of TGF-~ 1 did exhibit mild to severe lesions characteristic of 
AD, with one animal from each treatment regimen not showing any lesions typical of 
AD. 
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All animals in the placebo groups or in the TGF-~ 1-treated groups were positive 
for AD lesions in the kidneys and the liver; most mink being scored as having moderate 
to severe pathology. 
Discussion 
Aleutian disease virus (ADV) causes a number of interesting disease syndromes 
in mink. These syndromes include decreased fertility, abortion, acute pneumonia in kits, 
and chronic and persistent infections, all severely impacting the profitability of mink 
farming in Utah and throughout the world. Interestingly, the main feature of AD in 
susceptible adult mink is chronic, but fatal immune complex-mediated 
glomerulonephritis comparable to that seen in human disease such as systemic lupus 
erythematosus (Bloom, 1984 ). Because of its comparative aspects to human diseases and 
the substantial economic loss to the fur industries in the world, classical Aleutian disease 
and the nature of the virus has been studied extensively for 3 decades (Alexandersen, 
1990). 
Recently, several studies have been done to understand how the virus disturbs 
host immune function (Aasted and Leslie, 1991). From these studies, it has become 
apparent that the initial target for ADV replication is probably the macrophage found in 
the medullary sinuses of the lymph nodes of infected mink (Kanno et al., 1992). 
Secondary targets are B lymphocytes, circulating macrophages and follicular dendritic 
cells. The phenotype of Aleutian disease is characterized by extreme 
hypergammaglobulinemia caused by the production of non-neutralizing anti-ADV 
antibodies (Alexandersen, 1990) and polyclonal antibody production, including anti-
DNA antibodies (Hahn and Hahn, 1983). Subsequently, plasmacytosis (Porter et al., 
1980), arthritis (Porter et al., 1973) as well as immune complex-mediated 
glomerulonephritis develops. These features suggest that some step in B cell 
development and/ or maturation is over-stimulated by ADV infection (Kanno et al., 
1992). 
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Several theories have been advanced to account for the hypergammaglobulinemia 
described above (Bloom et al., 1994). Among them are i) cytokines are produced in 
response to ADV infection of target cell macrophages that enhance B cell proliferation 
and maturation; ii) viral components (e.g., structural proteins) might directly stimulate B 
cell development and clonal expansion; iii) abnormal antigen presentation by infected 
macrophages might disturb subsequent B cell development and proliferation. 
In support of the first hypothesis are the findings of lsaka et al. (1993). The 
cytokine of special interest for this research is TGF-~, which consists of a group of 
multifunctional dimeric cytokines. Originally isolated from tumor cells, with molecular 
weights of 25 kD, TGF-~s exhibit pleiotropic effects. Among the important actions of 
TGF-~ proteins are the recruitment and activation of mononuclear cells, promotion of 
wound healing, fibrosis and angiogenesis, and a potent immunosuppressive action on 
numerous functions of T lymphocytes. There is now considerable evidence to support an 
important role for TGF-~ in both the regulation of extracellular matrix accumulation and 
the pathogenesis of glomerulosclerosis. Recently, Isaka et al. (1993) used an in vivo 
renal transfection technique (injection of liposome-bound TGF-~ cDNA into the rat renal 
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artery), which resulted in over-expression of TGF-~ 1 in glomeruli and induced marked 
extracellular matrix accumulation. These and other findings support a direct role for this 
cytokine in the pathogenesis of glomerulosclerosis. Since TGF-~ 1 is a disparate 
modulator of cell recruitment, proliferation and extracellular matrix phenotype for 
mesenchymal and non-mesenchymal cells, we wanted to investigate the role of this 
cytokine in the potential amelioration of the immunopathology in the kidneys and liver of 
animals with AD. 
From the data of the cunent experiments, it is apparent that treated animals (TGF-
~1 at 100 and 200 ng/kg) had low antibody titers and BUN, IFN-y and CIC levels, most 
lower than those levels detected in placebo-treated mink (see summary Table 2.4). The 
infected placebo- and TGF-~ 1 inhibitor-treated animals all died by four months. These 
animals had high antibody titers and high BUN, IFN-y and CIC values and pathology 
attributable to AD, suggesting that the kidneys were damaged by immune complex 
deposition, a hallmark of AD. In a comparison of survival times between infected TGF-
~1-treated and placebo- and TGF-~ 1 inhibitor-treated animals, TGF-~ 1-treated animals 
receiving 100 or 200 ng/kg TGF-~ 1 survived almost twice as long as untreated animals or 
inhibitor-treated mink. Also, PCR assay of lymph node tissue confirmed that infected 
placebo- and TGF-~ 1 inhibitor-treated animals had significant levels of virus whereas 
animals treated with at 100 or 200 ng/kg TGF-~ 1 had none. These findings support the 
hypothesis that TGF-~ 1 treatment does ameliorate the severity of AD in mink. 
The effect of TGF-~ 1 treatment on just the animals surviving the 9-month 
experiment duration was assessed using the previously parameters described. Mink 
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treated with TGF-~ 1 at 200 ng/kg in all groups (group 1, 2, 3, and 4) lost significantly less 
weight than the control group mink (p < 0.01), although all surviving animals did lose 
some weight throughout the experiment (Table 2.4). Serum levels of BUN, IFN-y and 
CIC were significantly decreased from what was detected in placebo-treated mink (p < 
0.01, Table 2.4). Eleven animals (11/16) in the 200 ng/kg group and 9/13 in the 100 
ng/kg treated-group had no pathology attributable to AD. No virus was detected in almost 
all of the surviving animals. The antibody titer specific for ADV was also significantly 
lower than the titer in mink from the control group (p:::; 0.01) and typical for animals 
exposed to disease that are long-term survivors. These results lend credence to the 
conclusion that the various treatment regimens with TGF-~ 1 at 100 or 200 ng/kg provide 
a protective effect against chronic, lethal AD, even when administered after virus 
exposure. However, dosing at 1 ng/kg was not very effective. 
The data in this study support the idea that a dosing regimen of TGF-~ 1 at 100 
ng/kg significantly increases the survival time of mink after exposure to ADV. 
Nevertheless, a small number of mink still succumbed to the chronic effects of ADV 
exposure. All parameters measured indicated that using the TGF-~ 1 dose of 100 ng/kg 
injected 8 h after virus injection (group 2 dosing regimen) was not effective in delaying 
time to death, but that the severity of the disease was lessened within the time period 
studied in that particular treatment group (Table 2.4). All parameters measured in a 
subset of the TGF-~ 1 at 100 ng/kg treatment group treated with which survived were 
comparable to those measured in the infected control group. However, in the survivor 
group, mild to moderate lesions were still found despite treatment, and weight gains were 
less, lending credence to the supposition that treatment may only delay the time to death 
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and appearance of severe lesions, but not permanently alter the course of a chronic AD 
infection. Similar results were seen with the TGF-131 at 200 ng/kg treatment regimen. 
Time to death was extended substantially and the measured parameters in surviving mink 
were similar to the TGF-131 at 100 ng/kg group, but again pathology attributable to AD 
was still detected in the kidneys and liver of a small group of treated animals (Table 2.4 ). 
Interestingly, a parameter that seemed predictive of a negative outcome was the presence 
of high levels of interferon-y, a Th 1 cytokine. Interferon-y has also been shown to 
correlate with pathogenesis in another immune complex-mediated disease, systemic lupus 
erythematosus (Kuroiwa and Lee, 1998). In knock-out mice, interferon-y apparently was 
an important cytokine in amplifying the local immune responses of lupus induced 
nephritis. Infiltrating mononuclear cells exerted their effects on resident renal cells 
through secretion of soluble factors and apparent promotion of cell-to-cell contact. This 
scenario may not be the case with AD because in AD large numbers of lymphocytes are 
found at the lesion and not macrophages/monocytes. Instead, the high interferon-y levels 
could activate localized cytotoxic T cells by stimulating expression of MHC class I 
antigen cells on putative target cells (De Maeyer and De Maeyer-Guignard, 1998), for 
example, cells of the basement membrane coated with immune complexes. The latter 
scenario may correlate with our findings that infiltrating lymphocytes are often at the site 
of lesions associated with AD. 
Whereas high levels of interferon appeared to be a predictor of a negative 
outcome, high levels of TGF-131 bode well as a harbinger of survival for AD-infected 
mink (Table 2.4). The 100 and 200 ng/kg doses that seemed to ameliorate the disease in 
infected mink were also characterized by high serum levels of TGF-131, seemingly 
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supporting our hypothesis. This is further strengthened by the fact that mink treated with 
an inhibitor of TGF-~ 1 had much lower levels of TGF-~ 1 in their sera and h~d disease 
equal in severity, if not greater severity, than the untreated, control animals. 
From the data shown in this study, it is readily apparent that 100 ng/kg or a 200 
ng/kg dosages of TGF-~ 1 were most effective in treating ADV-infected mink; the TGF-~ 1 
at 1 ng/kg regimen failed to protect most mink from lethal chronic AD. The experimental 
design did not allow the determination of whether the compounds ameliorated the 
severity of the pathogenesis permanently, whether the lesion damage was reversible or 
irreversible or if the compounds "cured" mink of the disease. However, the lack of 
detection of viral DNA and the reasonably low levels of specific ADV antibody and 
circulating immune complexes all suggest that the virus was cleared, thus eliminating a 
continual stimulator of what appears to be type III hyper- sensitivity response. This 
would support the notion that at the very least, TGF-~ 1 at 200 and 100 ng/kg dosages can 
temporarily halt or significantly slow down the progression of the disease. 
A venues of future research may include more practical ways to administer TGF-
~1 to the mink, such as by vaccination in a similar way to how the vaccination for 
distemper is given. Perhaps it would be possible to combine TGF-~ 1 with one of the 
vaccines that is regularly given to mink and administer both at the same time in one 
injection thus being less labor-intensive for the farmer, or perhaps evaluated orally as part 
of the diet to see if it could be effectively administered as a supplement in the feed. 
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Table 2.1 
Effect of intravenous TGF-S 1 treatment on circulating immune complexes (CIC) in mink with Aleutian disease. 
Mean Circulating-Immune-Com2lex (~g E/ml ± SD) 
Group 1 (treated 2 weeks Group 2 (treated 8 h Group 3 ( treated 2 weeks 
2re-virus inoculation) QOSt-virus inoculation) QOSt-virus inoculation 
Pre-virus Post-virus Pre-virus Post-virus Pre-virus Post-virus 
Treatment Exposure Exposure b Exposure Exposureb Exposure Exposure b 
TGF-131 200 ng/kg 2.95 ± 0.90 8.25 ± 0.95* 3.12 ± 1.19 7.98 ± 1.59* 2.92 ± 1.37 9.09 ± 3.00*f 
TGF-131 100 ng/kg 2.81 ± 0.60 4.41 ± 0.74* 2.95 ± 0.56 3.51 ± 0.35* 2.81 ± 0.89 5.22 ± 1.85* 
TGF-131 1 ng/kg 2.76 ± 0.73 15.49 ± 1,97+ 2.98 ± 1.16 16.36 ± 2.27*f 2.69 ± 0.98 17.15 ± 2.88*f 
TGF-131-Inhibitor 2.68 ± 1.24 36.46 ± 9.02+ 2.85 ± 1.22 34.52 ± 7.52+ 3.06 ± 1.72 30.79 ± 3_99+ 
Placebo 2.98 ± 0.77 28.44 ± 6.15+ 3.11 ± 1.58 32.85 ± 5.95+ 2.76 ± 1.12 35.84 ± 4.36+ 
~GF-S 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation. 
bRepresents data from the last serum sample taken prior to death or sacrifice of the animal. 
cND = Not Done 
*p :$ 0.05 compared to placebo-treated controls. 


















Detection of ADV DNA in mink treated intravenously with TGF-P1. 
Presence of viral DNA Percentage of 
mink positive 
Group No. Treatment ADV+ ADV- for viral DNA a 
Group 1 TGF-P1 200 ng/kg 0 5* 0 
( treated 2 weeks TGF-P1 100 ng/kg 0 5* 0 
pre-virus TGF-P1 1 ng/kg 3 2 60 
inoculation) TGF-P 1-Inhibitor 4 1 80 
Placebo 4 1 80 
Group 2 TGF-P 1 200 ng/kg 0 5** 0 
(treated 8 h TGF-P1 100 ng/kg 0 5** 0 
post-virus TGF-P1 1 ng/kg 3 2 60 
inoculation) TGF-~ 1-lnhibitor 5 0 100 
Placebo 5 0 100 
Group 3 TGF-~ 1 200 ng/kg 1 4* 20 
(treated 2 weeks TGF-~1 100 ng/kg 0 5** 0 
post-virus TGF-~1 1 ng/kg 3 2 60 
inoculation) TGF-~ 1-Inhibitor 4 1 80 
Placebo 5 0 100 
Group 4b TGF-~1 200 ng/kg 0 5 0 
(3 treatments) 
aLymph nodes of animals were harvested and evaluated for the presence of viral 
DNA upon death or at the determination of the experiment. 
bTGF-~ 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-
virus inoculation 
*p ~ 0.05 compared to placebo-treated controls. 
**p ~ 0.01 compared to placebo-treated controls. 
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Table 2.3 
Summary of histopathological findings of AD-infected mink treated with TG~-f31• 
Histopathological Examination 
Percentage of 
Pathology Severity animals AD+ by 
Scores Pathology 
Group No. Treatment 0 + ++ +++ % 
Group 1 TGF-f31 200 ng/kgb 3 1 0 0 25 
(treated 2 weeks TGF-f31 100 ng/kg 3 1 1 0 40 
pre-virus TGF-f31 1 ng/kg 1 1 2 1 60 
inoculation) TGF-f31-Inhibitor c 0 1 2 0 100 
Placebob 0 2 2 0 100 
Group 2 TGF-f31 200 ng/kg 3 1 1 0 40 
(treated 8 h TGF-f31 100 ng/kg b 3 1 0 0 25 
post-virus TGF-f31 1 ng/kg b 1 1 2 0 75 
inoculation) TGF-f31-Inhibitor 0 0 3 2 100 
Placebo 0 1 3 1 100 
Group 3 TGF-f31 200 ng/kgc 2 0 1 0 33 
(treated 2 weeks TGF-f31 100 ng/kg b 3 0 1 0 25 
post-virus TGF-f31 1 ng/kg b 1 1 2 0 75 
inoculation) TGF-f31-lnhibitor 0 0 3 2 100 
Placebo 0 1 4 0 100 
Group 4a TGF-f31 200 ng/kg b 3 0 1 0 25 
(3 treatments) 
aTGF-f31 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-
virus inoculation. 
bOne animal from this group (n=5) died from bacterial infection or other causes not 
attributable to AD pathology. 
cTwo animals from this group (n=5) died from bacterial infection or other causes not 
attributable to AD pathology. 
Table 2.4 
Summar~ of results from 8 months treatment of Aleutian mink disease with TGF-~ 1. 
a 
Mean survival time % AD(+) Reciprocal Average(± SD) 
Group Treatment (day± SD) Alive/total Viral DNA Patholoy CEPTiter Weight (g) BUN (nm) IFN-y (µM) CIC (nm) TGF-~(ng/ml) 
Group I 200 ng/kg 207 ± 21 * 3/5* 0 25 358 ± 64** 828 ± 87* 17.9 ± 4.9* 18.l ± 3.3* 8.3 ± 1.0* 0.95 ± 0.07* 
(treated 100 ng/kg 221 ±26* 3/5* 0 40 307 ± 57** 820 ± 114* 14.l ± 3.5* 12.0 ± l.7* 4.4 ± 0.7* 0.91 ± 0.06* 
2 weeks Ing/kg 170 ± 31 1/5 60 60 614 ± 150* 730 ± 120* 31.3 ± 7.0* 25.0 ±4.2 15.5 ± 2.0 0.77 ±0.02 
pre-virus Inhibitor< 116±9** 0/5 80 100 1126 ± 280 340 ± 22 84.J ± 17.4 40.9 ± 7.0 36.5 ± 9.0 0.55 ± 0.07* 
inoculation) Placebod 149± 8 015 80 JOO 1024 ±0 339 ± 24 63.8 ± 12.7 31.6 ± 2.8 28.4 ± 6.2 0.73 ± 0.05 
Group 3 200 ng/kg 204 ± 9* 3/5* 0 40 410 ± 64** 808 ± 65* 23.l ±5.2* 15.5 ± 5.6* 8.0 ± 1.6* 0.88 ± 0.11 * 
(treated 100 ng/kg 247 ± 17* 3/5* 0 25 218±43** 883 ± 94* 15.3 ± 3.4* 17.6 ± 4.9* 3.5 ± 0.4* 0.88 ± 0.07* 
8h I ng/kg 170 ± 38 1/5 60 75 563 ±140** 765 ± 145 33.2 ± 11.8 25.0 ± 5.3* 16.4 ± 2.3* 0.77 ±0.03 
post-virus Inhibitor 123 ± 12 0/5 100 100 1024 ±0 373 ± 22* 73.2 ± 18.3 39.8 ± 6.2 34.5 ± 7.5 0.67 ±0.03 
inoculation) Placebo 120 ± 25 0/5 100 100 922 ± 115 470 ± 60 56.6 ±9.2 37.3 + 4.2 32.9 + 6.0 0.73 + 0.04 
Group 3 200 ng/kg 200 ± 33* 2/5 20 33 307 ± 57** 788 ± 103* 22.8 ±4.5* 16.6 ± 2.4* 9.1 ± 3.0* 0.84 ± 0.11 * 
(treated 100 ng/kg 223 ± 28** 3/5* 0 25 327 ± 88** 853 ± 100* 15.1 ± 7.0* 16.9 ± 3.6* 5.2 ± 1.9* 0.84 ± 0.06* 
2 weeks l ng/kg 179 ± 31 1/5 60 75 666 ± 128* 655 ± 53* 29.2 ± 8.2* 23.9 ± 8.8 17.2 ± 2.9* 0.77 ± 0.03 
post-virus Inhibitor 135 ± 26 0/5 80 100 922 ± 115 380 ± 37 61.8 ± 15.7 50.4 ± I 1.0 30.8 ± 4.0 0.62 ± 0.11 * 
inoculation) Placebo 129 ± 24 015 100 100 1126±280 365 ± 39 67.6 ± 5.0 42.0 ± 11.3 35.8 ± 4.4 0.74 ±0.02 
Groue 4b 200 ng/kg 248 ± 31 ** 3/5* 0 25 256 ± 29 969 ± 103 10.4 ± 2.7* 16.0 ± 4.8* 4.2 ± 0.8* 1.07 ± 0.26* 
3Values are averages of last measurable parameters prior to death or sacrifice. 
b3 times treatment: TGF-~ 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation. 
cLatency associated peptide, recombinant human (LAPrhTGF-~ 1 at 500 ng/kg). ct Control; PSS 0.1 % BSA 




























































TGF 200 ng/kg TGF 100 ng/kg TGF Ing/kg TGF-Inhibitor 
Treatment (8 months) 
**/++ 
*I *I+ 
Group 1 Group 2 Group 3 
Ell Group 1 
□ Group 2 




□TGF 200 ng/kg 
□ TGF I 00 ng/kg 




Fig. 2.2. Effect of intravenous TGF-~ 1 treatment on survival time of mink with Aleutian 
disease. Animals dying prior to day 266 days. TGF-B, was administered 2 weeks pre-, 8 
h post-, and 2 weeks post-virus inoculation. After 5 months, all animals in TGF-~, 
inhibitor group and the placebo group had died from AD. 
*p < 0.05 and **p < 0.01 compared to placebo group. 
+p < 0.05 and ++p < 0.01 compared to inhibitor group. 
76 
(A) 
1200 □ TGF 200ng/kg □ TGF lOOng/kg 
□ TGF Ing/kg 
m Inhibitor 




















2wk 1 2 3 4 5 6 7 8 







ti 800 on 
'-" ..... 
..c: on 










2wk 1 2 3 4 5 6 7 8 





















2wk 1 2 3 4 5 
Survival tirre (months) 
6 
ii TGF 200 ng/kg 
(£1 TGF 100 ng/kg 
OTGF 1 ng/kg 
~Inhibitor 
■Placebo 
DI G4:TGF 200 ng/kg 
7 8 
77 
Fig. 2.3. Effect of intravenous TGF-~ 1 treatment on body weights of mink with Aleutian 
disease. Group 1: treated with TGF-~ 1 injected 2 weeks pre-virus inoculation (A), Group 
2: TGF-~ 1 injected 8 h post-virus inoculation (B), and Group 3: TGF-~, injected 2 weeks 
post-virus inoculation and Group 4: TGF-~ 1 injected 3 times (2 weeks pre-, 8 h post-, and 
2 weeks post-virus inoculation) (D). Animals treated with recombinant human TGF-~1 
(rhTGF-~ 1) at 200, 100, and 1 ng/kg. Inhibitor: recombinant human latency associated 
peptide TGF-~ 1 (rhLAPTGF-~ 1) at 500 ng/kg. Placebo: 0.1 % BSA in PSS. After 5 
months, all animals in TGF-~ 1 inhibitor group and the placebo group had died from AD: 
*p < 0.05 compared to placebo group. 
**p < 0.01 compared to placebo group. 
+ p < 0.05 compared to inhibitor group. 
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Fig. 2.4. Effect of TGF-~ 1 treatment on the anti-ADV antibody titers in mink. Group 1: 
treated with TGF-~ 1 injected 2 weeks pre-virus inoculation (A), Group 2: TGF-~ 1 injected 
8 h post-virus inoculation (B), and Group 3: TGF-~ 1 injected 2 weeks post-virus 
inoculation and Group 4: TGF-~ 1 injected 3 times (2 weeks pre-, 8 h post-, and 2 weeks 
post-virus inoculation) (C). Animals treated with recombinant human TGF-~, (rhTGF-
~1) at 200, 100, and 1 ng/kg. Inhibitor: recombinant human latency associated peptide 
TGF-~ 1 (rhLAPTGF-~ 1) at 500 ng/kg. Placebo: 0.1 % BSA in PSS. After 5 months, all 
animals in TGF-~ 1 inhibitor group and the placebo group had died from AD. 
*p < 0.05 compared to placebo group. 
**p < 0.01 compared to placebo group. 
+ p < 0.05 compared to inhibitor group. 
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Fig. 2.5. Effect of intravenous TGF-~ 1 treatment on blood urea nitrogen (BUN) levels in 
mink with Aleutian disease. Group 1: treated with TGF-~ 1 injected 2 weeks pre-virus 
inoculation (A), Group 2: TGF-~ 1 injected 8 h post-virus inoculation (B), and Group 3: 
TGF-~ 1 injected 2 weeks post-virus inoculation and Group 4: TGF-~ 1 injected 3 times (2 
weeks pre-, 8 h post-, and 2 weeks post-virus inoculation) (C). Animals treated with 
recombinant human TGF-~ 1 (rhTGF-~ 1) at 200, 100, and I ng/kg. Inhibitor: recombinant 
human latency associated peptide TGF-~ 1 (rhLAPTGF-~ 1) at 500 ng/kg. Placebo: 0.1 % 
BSA in PSS. After 5 months, all animals in TGF-~ 1 inhibitor group and the placebo group 
had died from AD. 
*p < 0.05 compared to placebo group. 
**p < 0.01 compared to placebo group. 
+p < 0.05 compared to inhibitor group. 
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Fig. 2.6. Effect of intravenous TGF-~ 1 treatment on serum interferon gamma (IFN-y) 
levels in mink with Aleutian disease. Group 1: treated with TGF-~ 1 injected 2 weeks pre-
virus inoculation (A), Group 2: TGF-~ 1 injected 8 h post-virus inoculation (B), and 
Group 3: TGF-~ 1 injected 2 weeks post-virus inoculation and Group 4: TGF-~ 1 injected 3 
times (2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation) (C). Animals treated 
with recombinant human TGF-~ 1 (rhTGF-~ 1) at 200, 100, and 1 ng/kg. Inhibitor: 
recombinant human latency associated peptide TGF-~ 1 (rhLAPTGF-~ 1) at 500 ng/kg. 
Placebo: 0.1 % BSA in PSS. After 5 months, all animals in TGF-~ 1 inhibitor group and 
the placebo group had died from AD. 
*p < 0.05 compared to placebo group. 
**p < 0.01 compared to placebo group. 
+p < 0.05 compared to inhibitor group. 
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Fig. 2.7. Effect of intravenous TGF-B 1 treatment on serum TGF-B 1 levels in mink. Group 
1: treated with TGF-B I injected 2 weeks pre-virus inoculation (A), Group 2: TGF-B, 
injected 8 h post-virus inoculation (B), and Group 3: TGF-B, injected 2 weeks post-virus 
inoculation and Group 4: TGF-B 1 injected 3 times (2 weeks pre-, 8 h post-, and 2 weeks 
post-virus inoculation) (C). Animals treated with recombinant human TGF-B 1 (rhTGF-
B1) at 200, 100, and 1 ng/kg. Inhibitor: recombinant human latency associated peptide 
TGF-B 1 (rhLAPTGF-B 1) at 500 ng/kg. Placebo: 0.1 % BSA in PSS. After 5 months, all 
animals in TGF-B, inhibitor group and the placebo group had died from AD. 
*p < 0.05 compared to inhibitor group. 
+p < 0.05 compared to placebo group. 
CHAPTER3 
EFFECTS OF HE 2300 AND HE 2500 ON THE OUTCOME OF 
ALEUTIAN DISEASE IN MINK 
Abstract 
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Aleutian disease of mink (AD) is an immunopathological disorder of mink 
induced by persistent infection with AD virus. Many breeds of mink seem to have a high 
a susceptibility to AD. 
Interestingly, the primary feature of AD in susceptible adult mink is a chronic, 
fatal immune complex-mediated glomerulonephritis comparable to that seen in human 
diseases such as systemic lupus erythematosus. Currently no therapies are available and 
vaccination has been a failure; the latter exacerbates the disease. 
The hypothesis to be tested in this research was that dehydroepiandrosterone-like 
compounds (DHEA analogs) will inhibit or ameliorate Aleutian disease in mink. The 
DHEA analog, HE2300 and HE2500, used three times weekly at 13 mg/ml, significantly 
enhanced mink survival time compared to infected, untreated control mink. The severity 
of the disease was lessened as determined by histopathological examination. HE2300 
(3x/wk) treatment increased survival time and body weight nearly two-fold compared to 
infected, untreated animals. Untreated animals had high antibody titers and high blood 
urea nitrogen (BUN), creatinine, alanine aminotransferase (ALT), asparatate 
aminotransferase (AST), interferon gamma (IFN-y), and circulating immune complex 
(CIC) levels, suggesting immune complex deposition, a hallmark of AD. Infected, 
treated animals showed a dramatic decrease in ADV-specific antibody titers. BUN, 
87 
creatinine, ALT, AST, IFN-y, and CIC levels. This was supported by histopathological 
examination of the mink. Spleen weights of untreated animals increased by two-fold 
compared to treated animals and control mink. 
Another analog, HE2500, also ameliorated AD in mink when given three times 
weekly at a dose of 16 ng/kg. Time to death was extended in treated mink and all other 
parameters measured were similar to the uninfected control animals, although usually 
mild lesions were present in kidney and liver of surviving mink in the treated group. 
These findings support the hypothesis that DHEA analogs may be able to promote 
an immune responses that affords protection for mink from chronic lethal AD. 
Introduction 
Aleutian disease virus (ADV) causes a number of interesting and completely 
different disease syndromes in mink. These syndromes include decreased fertility, 
abortion, acute pneumonia in kits, and chronic and persistent infections, all severely 
impacting the profitability of mink farming. Interestingly, the primary feature of 
Aleutian disease (AD) in susceptible adult mink is a chronic, fatal immune complex-
mediated glomerulonephritis comparable to that seen in human diseases such as systemic 
lupus erythematosus (Bloom, 1984). Currently no therapies are available and vaccination 
has been a failure; the latter exacerbated the disease (Alexandersen, 1990). For producers 
who have AD in their mink, their only recourse is to kill the mink early before the coat of 
the animal becomes less desirable due to AD effects, or when time to harvest the pelts 
comes to gamble that the disease will not afflict a significant portion of their animals. 
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Therefore, a need exists to develop a modality that can boost the susceptible animals' 
immune responses in an appropriate manner to allow them to survive the disease. 
Despite intensive studies, the mechanism by which ADV induces a severe 
disorder of immune function and establishes a chronic, persistent infection remains 
unclear. It is also not well established whether inbreeding of the animals may be part of 
the problem. The mink have been so extensively inbred that certain varieties (e.g., 
sapphires, a.k.a. Aleutian mink) may not be immunocompetent. 
Recently, several studies have been done to understand how ADV disturbs host 
immune function (Aasted and Leslie, 1991; Mori et al., 1991; Kanno et al., 1992). From 
these studies, it has become apparent that the initial target for ADV replication is 
probably the macrophage found in the medullary sinuses of the lymph nodes of infected 
mink (Kanno et al., 1992). Secondary targets are B lymphocytes, circulating 
macrophages and follicular dendritic cells. The phenotype of AD is characterized by 
extreme hypergammaglobulinemia caused by the production of non-neutralizing anti-
ADV (Alexandersen, 1990) and polyclonal antibody production, including anti-ADV 
DNA antibodies (Hahn and Hahn, 1983). Subsequently, plasmacytosis (Porter et al., 
1980), arteritis (Porter et al., 1973), as well as immune complex-mediated 
glomerulonephritis, develops. These features suggest that some step in B cell 
development and/ or maturation is overstimulated by ADV infection (Kanno et al., 1992). 
Several theories have been advanced to account for the hypergammaglobulinemia 
described above (Kanno et al., 1992). Among them are i) cytokines are produced in 
response to ADV infection of target cell macrophages that enhance B cell proliferation 
and maturation; ii) viral components (e.g., structural proteins) might directly stimulate B 
cell development and clonal expansion; iii) abnormal antigen presentation by infected 
macrophages might disturb subsequent B cell development and proliferation. 
In support of the first hypothesis are the findings of Bloom et al. ( 1994) that 
macrophages produce interleukin-6 (IL-6) in antibody-dependent ADV infection. In 
addition, IL-6 mRNA can be detected in the mesenteric lymph nodes of ADV-infected 
mink. Perhaps not coincidentally, human diseases that are characterized by 
hypergammaglobulinemia are also associated with high levels of IL-6 production (e.g., 
Castleman's disease). Thus, AD may be a virus-induced cytokine disorder; a syndrome 
of chronic, inappropriate production of IL-6 and perhaps other cytokines (Bloom et al., 
1994). 
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A pertinent observation for the treatment of AD in mink is that an attenuated 
vaccine only enhances the disease, leading to an especially extreme B cell hyperplasia, 
while immunosuppressive therapy has been shown to somewhat ameliorate the severity 
of disease, e.g., preventing Aleutian disease lesions (Cheema, et al., 1972). These 
therapies have only produced marginal results. One of the compounds chosen, 
levamisole, does not directly modulate the B cell function of producing of antibody 
(Amery and Harig, 1984). The other compound, isoprinosine, actually enhances B cell 
antibody production in the presence of pokeweed mitogen (Tsang et al., 1984), perhaps a 
less than desirable effect in AD where over-production of antibody leads to fatal disease. 
The ~-androstene steroids form a subgroup of steroids that up-regulate immunity, 
increases resistance against lethal infection and lethal radiation, and mediate a rapid 
recovery of hematopoietic precursor cells after radiation injury. In vivo, the ~-
androstenes increase the levels of the Th 1 cytokines such as IL-2, IL-3, IFN-y; they also 
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counteract hydrocortisone immune suppression, and function in the maintenance of the 
Th 1/ Th2 balance and immune homeostasis. 
There is considerable evidence for an immunomodulatory role for a cytokine, 
dehydroepiandrosterone (DHEA), ~-androstene. It both potentiates and inhibits various 
functions of the immune system in its regulatory role, depending on when and where it 
is expressed (Loria, 2002). However, its potent effects on immune cells in vitro are 
reflected in the various effects it has in various animal model systems, strongly 
suggesting an important role in immune disorders such as autoimmune disease (Derynck 
and Choy, 1998). DHEA, one of these ~-androstenes, has been shown to have 
immunomodulating effects in several experimental infections involving viruses and 
protozoans (Rasmussen et al., 1991; Mulder et al., 1992; Uozumi et al., 1996; Loria and 
Padgett, 1998). In HIV infections, 17a-bromoepiandrosterone (a-epi-Br), an analog of 
DHEA, may shift cytokine production to a Th 1 response and increase circulating 
activated immune effector cells (Freilich et al., 2000). This activity appeared not to be 
androgenic, since the compound only bound weakly to the androgen receptor. In 
contrast, the 17a-epimer of androstenetriol inhibits proliferation and mediates apoptosis 
in tumor cells of murine and human origin (Loria, 2002). The antiproliferative functions 
of 17a-androstenediol are not dependent on either the estrogen or androgen receptors. 
Thus, DHEA and its analogs may be able to promote Thl cytokine-type responses 
that could afford protection for mink from chronic lethal AD. Therefore, we attempted 
to develop several approaches for treating experimental AD using epiandrosterone 
analogs. We tested the hypothesis that treatment of AD-infected mink with TGF-~ or 
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epiandrosterone analogs would ameliorate the development of the AD as shown by an 
enhanced survival time and lessened other AD parameters in the animals. , 
Materials and Methods 
Animals 
Unmated or non-parous 1-year-old female mink weighing 600-1000 g were used. 
These mink were obtained from the Windy Peaks ranch facility (Franklin, ID). This 
facility has been free of AD for about 6 years as determined by serological testing and 
pathology results. All animals were tested for AD by counter-immune-electrophorsis 
prior to admittance to animal research facility. 
Mink were fed a one-time daily ad libitum diet (approximately 100 g) with a fish-
based diet formulated for optimal growth, pelt quality, and seasonal variations in 
nutritional needs by the Mink Farmer's Cooperative of Utah. 
Blood for analysis was obtained by toe clip, and when mink were sacrificed, they 
were euthanized by carbon monoxide inhalation in a sealed plexiglass chamber in an 
aerated room. 
Animals were held to up to 8 months. Signs of disease were measured monthly 
by analyzing serum samples using antibody, blood urea nitrogen, interferon gamma, and 
circulating immune complex assays. Confirmation of disease was measured by 
histopathology examination of kidney, liver, and spleen and by detection of viral DNA in 
mesenteric lymph nodes. In addition, animals were monitored monthly to determine 
weight loss or gain, weight loss being a symptom of AD. 
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Study Design 
Five mink received 16 ng/kg of HE2300 (~-androstenetriol (~-AET); 5-
androstene-3~-7~-triol; Hollis-Eden pharmaceuticals, San Diego, CA) once per week, 17 
animals received 16 ng/kg of HE2300 three times per week and five animals were 
injected with 16 ng/kg of HE2500 (fluasterone [FLST]; 16a-fluoro-5-androsten-17-one; 
Hollis-Eden pharmaceuticals, San Diego, CA) three times per week. In addition, 17 
animals received vehicle three times per week. All treatments were injected 
subcutaneously into the nape of the neck of the mink. In addition, six animals only 
received virus (Table C. l ). All animals exposed to virus were injected with virus 
intraperitoneally and received 5 X 105 fluorescent focusing units of ADV of mink (Strain 
Utah I). Five animals did not receive virus or any treatment. Treatment began 8 h after 
virus exposure. 
Cell 
The macrophage cell line RAW 264.7 was obtained from American Type Culture 
Collection (Manassas, VA, USA.). The cells were routinely passaged with in Dulbecco's 
modification of minimal essential medium (GIBCO Invitrogen Corporation, Grand Island, 
NY, USA) containing 4000 mg/L glucose. The medium was supplemented with 4 mM 
L-glutamine (GIBCO Invitrogen Corporation), 0.1 mM sodium pyruvate (GIBCO 
Invitrogen Corporation), 0.15% sodium bicarbonate and 10% fetal bovine serum 
(Hyclone Laboratories, Logan, UT). 
Counter Current lmmunoelectrophoresis 
CEP was done according to the manufacturer's instructions using commercially 
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available reagents (United Vaccines, Madison, WI). Briefly, the samples were run on 80 
X 100 mm agarose gels into which wells had been punched. Known antigen plus serum 
dilutions from the infected animal were placed in wells in apposition to one another. The 
gels were exposed to electrical current at a constant 40 volts for 1 h. Titers of antibody 
for each treatment were calculated by taking the inverse of the last dilution at which 
precipitation was detected using the last available serum prior to death. These titers were 
then averaged for each treatment group. 
Interferon-y Bioactivity Assay 
This assay was used as an indicator of a Thl cellular response. A nitric oxide 
production bioassay for interferon-y was used to assay for interferon-yin serum samples 
(Kim and Son, 1996). RAW cells, a murine macrophage cell line (American Type 
Culture Collection, Manassas, VA), were seeded at 1 X 105 cells per well in a 96-well 
flat-bottomed plate (Coming Costar, NY) and incubated at 37°C for 6 h. The cells were 
then exposed to a known interferon stimulator or a filtered serum sample for 24 h at 
37°C. Nitric oxide produced in response to interferon induction in the cells was detected 
by the addition of dimethyl-a-naphthylamine, yielding a red color. Absorbances were 
detected spectrophotometrically at a wavelength of 540 nm. Absorbances were converted 
to nitrite concentration (µ,M) using a standard curve for each assay done. 
Circulating Immune Complex (CIC) Assay 
This serum-based assay was done by following the instructions of a commercially 
available CIC kit (APLPCO Diagnostics, Windham, NH) to quantitate the amount of CIC 
found in each mink serum sample. 
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CICs normally activates complement when they are formed in the host and are 
normally cleared by phagocytosis. The component of the complement systetn that binds 
these complexes is complment-lq (Clq). For this assay Clq was used to capture any 
immune complexes found in serum samples. CIC binding to Clq was detected using an 
alkaline phosphatase conjugated Protein A, which binds to the Fe region of IgG, the 
predominate antibody associated with immune complexes (Wehler et al., 1981). 
Dilutions of mink sera (beginning at 1 :50 dilution) or standards and controls were 
incubated with human Clq pre-adsorbed onto microtiter wells for 1 h at room 
temperature. The detection protocol of the kit was then followed. Absorbance at 405 nm 
was read. CIC concentrations detected in various mink sera were calculated from 
standard curves generated using the positive controls provided in the kit. 
Blood Chemistry Evaluations 
Blood chemistry profiles of sera were determined using a calibrated blood 
chemistry analyzer at Logan Regional Hospital (Logan, UT). A 15 parameter protocol 
was used and included detection of Ca+, Na+, K+ and er levels. Sera were also tested for 
the serum levels of the following: urea/nitrogen, creatinine, albumin, aspartate and 
alanine aminotransferases, total bilirubin, alkaline phosphatase, lactate dehydrogenase, 
glucose, and CO2• 
Polymerase Chain Reaction Detection of Viral DNA 
DNA was extracted from mesenteric lymphoid tissue using the DNeasy kit 
(Qiagen, Valencia, CA). For the PCR reaction the primers used were those described by 
Jackson et al. (1992). The reactions consisted of the following components: 49.5 µJ of 
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double distilled water. 0.25 µ,M concentration of each primer, 0.2 mM of all four 
dexyribonucleotide triphosphates, 50 mM KCL, 10 mM Tris-HCl (pH 8.8), 1.5 mM 
MgCl2, 0.2% Triton X-100, 2.5 units Tag DNA polymerase (Promega) and dilutions of 
DNA from the samples. For each gel run, there was a positive control, negative control 
and reagent control. PCR amplification was carried out using a thermal cycler in the 
following manner: 
Denaturation: 95°C for 1 min 
Primer annealing: 55°C for 1 min 
Primer extension: 72°C for 2 min 
Thirty cycles were performed. After amplification, samples were analyzed on a 
1.0% agarose gel in TAE buffer (Ausubel et al., 1987). Bands were visualized with 
ultraviolet light and photographed using Polaroid film. 
Histopathological Examinations. 
Upon the death of each mink, either from AD or when sacrified the kidneys and 
liverwere removed and tissues from each were sectioned, fixed and then stained with 
hematoxylin and eosin. Typical pathological findings for AD included thickened 
mesangium in the glomeruli with homogenous eosinophilic material (membranous 
glomerulopathy), detection of multifocal infiltrates of plasma cells and lymphocytes in 
the interstitium of the kidney cortex (interstitial nephritis) and also in the medulla, 
multiple convoluted tubules containing eosinophilic material or granular casts, occasional 
mineralization basement membranes, and portal areas of the liver with varying numbers 
of infiltrated plasma cells and lymphocytes (hepatitis) randomly dispersed among the 
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hepatocellular cords. Samples were coded and sent to a board certified pathologist (Utah 
State Veterinary Diagnostic Laboratory, Logan, UT), who examined the samples for the 
above-defined pathology; abnormalities were scored as mild ( + ), moderate ( ++ ), and 
severe ( +++ ). Samples with the pathology described above were considered positive for 
AD. 
Statistical Analysis 
Statistical significances were determined by analysis of variance and Student's t-
test where appropriate. Standard deviations (SD) were determined for all mean values. 
Log rank test was for distribution of survival equality in the two groups. In other 
words, log rank test was to test statistical significance of survival environment each 
infected-treated group compared to infected-untreated. Statistically, F-value and p-value 
of statistical significance were often reported. 
Results 
Effects of HE2300 and HE2500 Treatment on Physiological and Physical 
Parameters of Mink exposed the Aleutian Disease Virus 
Survival Time 
Mean and median survival times in the normal control group was eight months. 
All infected animals receiving no treatment presumably died from AD, since they all 
exhibited pathogical lesions consistent with AD. The mean and median survival times in 
the infected, untreated group was 3.8 and 4 months, respectively, which was significantly 
(p < 0.001) reduced compared to the 8 months survival time of the normal control group 
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(Fig. 3.1). Sixteen percent of the animals in the virus-infected group survived 4 months. 
' 
The null hypothesis that there was no difference in survival experience between the two 
groups was rejected. The mean and median survival time in the infected vehicle-treated 
group was 4 months in both cases, again a significantly reduction in survival time 
compared to control (log rank test, p < 0.01). Forty-seven percent in the vehicle group 
survived to 4 months of age. Only one animal survived 8 months in the vehicle-treated 
group exposed to virus. 
The mean and median survival times in the HE2500 (treated three times per 
week) group was 6 and 8 months, respectively. Sixty percent of the animals in this group 
survived to 4 months of age, compared to the vehicle and untreated virus control groups. 
However, one animal in this group apparently did not die from AD; the lesions were not 
consistent with ADV pathogenesis. Excluding that animal, the survival rate was 75% and 
the mean time to death was 7 months that is statistically different from vehicle and virus 
controls. Mink treated with HE2300 one time per week afforded the mink much less 
protection against lethal AD. These animals had a mean survival time of 4 months and 
only one animal (20%) in that group survived the 8 months duration of the experiment. 
By contrast, the mean and median survival time in HE2300 (treated three times per week) 
group was 7 and 8 months, respectively. Fifty-two percent in this group survived 4 
months, which was statistically significant compared to placebo-treated controls (p < 
0.05, log rank test). 
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Weight Gain 
Mink were weighed prior to any treatment and that weight was designated "pre-
exposure weight." The post-virus exposure weights represent the mean weight of 
animals in each treatment group just prior to death or sacrifice. The mink which were 
untreated and not exposed to virus (normal control animals) had significant weight 
increases relative to the infected untreated animals (p < 0.01, Fig. 3.2). Mink that were 
exposed to virus or virus plus vehicle had significant weight losses when compared to the 
average pre-exposure weights of the same animals. Animals exposed to virus and then 
treated with any of the treatment regimens gained weight similar to that of the normal 
controls and gained a significant amount of weight relative to vehicle-treated virus 
exposed mink and infected untreated mink (p < 0.01). 
Histopathological Findings 
Histopathogical examination of the dying or sacrificed animals exposed to ADV 
revealed the following results. Twenty-five percent of the mink treated with HE2500 
appeared to have no lesions associated with AD, while the remaining mink did exhibit 
lesions consistent with AD ranging in severity from mild to severe (Table 3.1). One 
animal in this group had particularly severe lesions and survived 5 months; the remainder 
survived the entire 8 months of the experiment (Table 3.2). 
All animals treated with HE2300 one time per week had lesions indicative of AD. 
When treated with same compound three times per week, two animals did not exhibit 
AD-like lesions, whereas 10 had a severity score of+ and five had a severity score of++. 
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No lesions specific for AD were detected in two animals treated with vehicle. However, 
four animals had lesions classified as mild and eight had lesions scored as moderate to 
severe. As expected, all untreated, virus-exposed mink demonstrated pathology 
attributable to AD. 
Serum Levels of Ions 
Maintaining of proper ion levels the serum is extremely important for homeostasis. 
When these levels are abnormal, they often reflect problems with absorption, usually at 
the level of the glomerular and tubules of the kidney. Since a hallmark of AD is 
glomerulonephritis and renal dysfunction, the serum levels of sodium, calcium, 
potassium, and chloride ions were monitored throughout the duration of the experiment. 
Mink that were infected and not treated or treated with placebo showed 
significantly (p < 0.05) increased levels of K+, Na+ and er relative to animals in other 
treatment groups (Fig. 3.3). These levels of K+, Na+ and er were also elevated when 
compared to levels in each animal prior to infection. Serum Ca +2 levels in the placebo 
and untreated groups dramatically dropped during the experiment and were significantly 
different from the other groups of mink. In treated animals, the levels of the ions 
remained relatively constant throughout the duration of the experiment. 
Serum Levels of Liver Enzymes 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are 
enzymes produced abundantly in hepatocytes and their release into the serum indicates a 
reduction in liver function, although diet (mink diet was rich in fish offal containing 
amines) may influence these enzyme levels to some extent. In mink treated with HE2500 
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and the one dose of HE2300 (three times per week), the serum levels of these two 
enzymes were not significantly different from the normal untreated, uninfect'ed controls 
(Fig. 3.4). However, the virus-infected mink receiving vehicle or no treatment had much 
higher (p < 0.05) serum levels of the two liver enzymes compared to the drug-treated 
infected animals. 
Serum Levels of Nitrogenous Compounds 
Detectable levels of urea, creatinine or other nitrogenous compounds in serum are 
usually indicative of damage to the kidneys, probably at the level of readsorption through 
the tubules. In mink treated with HE2300 (three times per week) and HE2500, the levels 
of urea/nitrogen were similar to the normal uninfected, untreated controls (Fig. 3.5). 
However, the levels of those metabolites in virus-infected mink receiving vehicle and in 
the untreated group of mink were significantly higher (p < 0.05) than drug-treated and the 
normal control groups. 
High serum creatinine levels are a sign of severe renal impairment, but such levels 
were not found in the serum at any significant amounts above or below the normal 
control group for the HE2300 (three times per week) and HE2500 group (Fig. 3.5). 
However, the levels of creatinine in virus-infected mink receiving vehicle and infected, 
untreated group were significantly higher (p < 0.05) than thedrug-treated and normal 
control group. 
Virus Levels 
Effects of HE2300 and HE2500 on Viral and Immunological 
Parameters in Mink Infected with ADV 
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Viral DNA was detected in the mesenteric lymph nodes of exposed mink by PCR 
amplification and gel analysis from samples taken as soon after death as possible or after 
sacrifice. Twenty percent of the mink treated with HE2500 were found to have viral 
DNA, 40% treated with HE2300 given one time per week were also positive for viral 
DNA and 18% of the mink treated with HE2300 three times per week were positive 
(Table 3.3). In the vehicle control animals, 71 % were positive and 83% of the mink 
exposed to virus only were also found to be positive for viral DNA. Only four mink 
receiving HE2300 treatment three times per week were positive for viral DNA and this 
was significantly lower than those infected and treated with placebo (p = 0.003). 
Specific ADV Antibody Levels 
High titers of antibody (>512) are often associated with progressive chronic AD 
(Bloom et al., 1994). Serum was analyzed for ADV-specific antibody by CEP assay. In 
mink treated with HE2500, the average titer upon death of the animal was 666, for mink 
treated with HE2300 one time per week, 339 and for mink receiving HE2300 three times 
per week, 337 (Fig. 3.6). In contrast, the average titers in vehicle-treated mink and in 
infected, but untreated mink were significantly higher, 1365 and 1536, respectively (p < 
0.001). All placebo animals were dead after 5 months, generally due to complications 
from AD. 
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Circulating Immune Complexs (CIC) Titers 
One of the hallmarks of AD pathology is the destruction of kidney tissue due to 
deposition of CIC in the kidney and subsequent complement-mediated destruction of the 
basement membrane of kidney tubules. Mink that were infected with virus and not 
treated or received vehicle had much greater CIC levels in their serum than the treatment 
group receiving HE2500 and significantly higher levels than those mink receiving either 
dose of HE2300 (p < 0.01, Fig. 3.7). Virus-infected mink that were not treated also had 
substantially higher levels of CIC than any of the compound treatment regimens. 
Serum Gamma Interferon (IFN-y) Activity 
Mink treated with HE2300 given three times per week had NO levels that were 
much less than were those detected in vehicle-treated mink or in virus-infected mink 
receiving no treatment (p < 0.01, Fig. 3.8). In addition, the mink treated with HE2500 or 
HE2300 given one time per week, the NO levels were significantly reduced as well (p = 
0.0345,and 0.007, respectively). Levels of NO with all drug treatments were very similar 
to the levels detected in uninfected, untreated mink. 
Splenomegaly 
Splenomegaly is a reflection of an active infection or any number of abnormalities 
including hypergammaglobulinemia, liver disorders and AD (Bloom et al., 1994). In 
mink with AD this is probably due the prodigious production of antibody (sometimes 100 
mg/dl) in response to virus infection. In this experiment, mink that were infected with 
ADV had much larger spleen weights than did control mink or mink treated with HE2500 
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or HE2300 (Fig. 3.9). In addition, the average spleen weight in untreated mink exposed 
to virus was significantly heavier than in unexposed, untreated mink (p < 0.01). 
Discussion 
Previous preliminary experiments run by us with HE2300 had indicated that 
treatment of ADV-infected mink three times per week increased the survival time of 
those mink (data not shown). The current experiments were done to verify those initial 
findings, as well as to evaluate a less frequent dosing regimen and to evaluate a new 
compound, HE2500, for efficacy in this immune complex disease model. 
HE2500 3x/wk 
The effects of treatment on surviving animals were assessed using the parameters 
discussed above. Mink treated with HE2500 had a significant reduction in weight gain 
compared to control mink (p < 0.001), although all surviving animals did gain some 
weight throughout the experiment (Table 3.2). Serum levels of nitrogenous compounds 
and liver enzymes were elevated, although not significantly different from what was 
detected in normal (uninfected/ untreated) mink. Only one animal in this group had no 
pathology attributable to AD, even though virus was not detected in any of the surviving 
animals (Table 3.4). Relative to the sole surviving animal in the vehicle-treated group, 
the ADV-specific antibody titers in the HE2500-treated animals were much lower as 
were the levels of CIC (p < 0.001), the latter being no different than those levels detected 
in the control animals. Interferon-y activity was also comparable to the untreated, 
uninfected control animals. 
A three times per week dosage regimen of HE2500 at 16 ng/kg dosage was 
effective in treating ADV-infected mink. The compounds appeared to delay the 
progression of the disease. 
HE2300 Ix/wk 
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One animal in this treatment group survived eight months. This mink did not 
significantly gain weight compared to the control mink, but unlike the surviving animal 
in the infected vehicle-treated group, it did not lose weight (Table 3.2). This animal had 
very definite lesions consistent with AD, although no virus was detected in the 
mesenteric lymph nodes (Table 3.4). The liver enzyme levels in the serum were quite 
elevated compared to the uninfected controls, but the serum levels of nitrogenous 
compounds were only slightly elevated compared to controls (Table 3.2). The antibody 
titer specific for ADV was much lower than that titer in the surviving mink from the 
vehicle-treated group and typical for animals exposed to disease that are long-term 
survivors (Table 3.4). The level of circulating immune complexes was commensurate 
with the low ADV-specific antibody titer and equivalent to that found in the control 
animals. Interferon-y activity was also similar to that detected in the uninfected control 
animals. Despite the favorable physiological and immunological outcomes, this mink did 
sustain moderate damage to the kidney and liver, which consisted of patchy membranous 
glomerulopathy, some multifocal interstitial nephritis, and hepatitis with infiltration of a 
few lymphocytes and plasma cells in the portal areas of the liver. 
A one time per week regimen of HE2300 at 16 ng/kg dosage failed to protect 
most mink from lethal chronic AD. 
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HE2300 3xlwk 
The mink in this treatment group also had significant reductions in weight gain 
(Table 3.2); five of the animals lost weight (10-140 g), although not as severe as the 
weight loss in the vehicle-treated animal, which lost half its original body weight (-450 
g). The remaining animals maintained their weight or gained weight (0-110 g). Only 
two mink in the HE2300 group did not have demonstrable AD lesions in the kidney and 
liver, while most remaining mink had moderate lesions in the kidney and liver with one 
animal having severe lesions. The blood urea/nitrogen serum levels were elevated 
relative to the normal (uninfected, untreated) controls, although the creatinine levels were 
similar to the normal controls (Table 3.2). Serum levels of the livers enzymes were 
elevated in this treatment group, although this was statistically not significant due to the 
variability in these measurements. Spleen weights were near normal as were the levels of 
CIC (Table 3.4). ADV specific antibody titers in this group were again typical for 
animals surviving a potentially lethal exposure to ADV ( <512). The large, pronounced 
level of interferon-y activity detected in the surviving vehicle-treated mink was not 
detected in the HE2300-treated mink and was actually no greater than those levels found 
in the uninfected control group. 
HE2300 given three times per week at 16 ng/kg was the most effective means of 
treating ADV-infected mink. The compounds temporarily halted or slowed down the 
progression of the disease. 
The data in the current study support the idea that a dosing regimen of three times 
per week with HE2300 significantly increases mink survival time after exposure to ADV. 
Nevertheless, substantial numbers of mink still succumbed to the chronic effects of ADV 
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exposure. All parameters measured indicated that HE2300, using the three times per 
week dosing regimen, was not only effective in delaying time to death, but that the 
severity of the disease was lessened within the time period studied in that particular 
treatment group. The parameters measured in a subset of the HE2300-treatment group, 
surviving mink, were all comparable to those measured in the uninfected control group 
with two exceptions, the pathology detected and weight gain. In the survivor group, mild 
to moderate lesions were still found despite treatment and weight gains were less, lending 
credence to the supposition that treatment may only delay the time to death and 
appearance of severe lesions, but not permanently alter the course of a chronic AD 
infection. 
Similar results were seen with the HE2500 treatment regimen. Time to death was 
extended substantially and the measured parameters in surviving mink were similar to the 
control group, but again pathology attributable to AD was still detected in the kidneys 
and liver of the treated animals. 
Interestingly, a parameter that seemed predictive of a negative outcome was the 
presence of high levels of interferon-y, a Thl cytokine. Interferon-y has also been shown 
to correlate with pathogenesis in another immune complex-mediated disease, systemic 
lupus erythematosus (Kuroiwa and Lee, 1998). In knock out mice, interferon-y 
apparently was an important cytokine in amplifying the local immune responses of lupus 
nephritis. Infiltrating mononuclear cells exerted their effects on resident renal cells 
through secretion of soluble factors and apparent promotion of cell-to-cell contact. This 
scenario may not be the case with AD because in AD large numbers of lymphocytes are 
found at the lesion and not macrophages/monocytes. Instead, the high interferon-y levels 
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could activate localized cytotoxic T cells by stimulating expression of MHC class I 
antigen cells on putative target cells (De Maeyer and De Maeyer-Guignard, 1998), for 
example, cells of the basement membrane coated with immune complexes. The latter 
scenario may correlate with our findings that infiltrating lymphocytes are often at the site 
of lesions associated with AD. 
From the data shown in this report, it is readily apparent that a three times per 
week regimen of either HE compound was most effective in treating ADV-infected mink; 
the one time per week regimen failed to protect most mink from lethal chronic AD. The 
experimental design did not allow the determination of whether the compounds 
ameliorated the severity of the pathogenesis permanently, whether the lesion damage was 
reversible or irreversible, or if the compounds "cured" mink of the disease. However, the 
lack of detection of viral DNA and the reasonably low levels of specific ADV antibody 
and circulating immune complexes all suggest that the virus was cleared, thus eliminating 
a continual stimulator of what appears to be type III hypersensitivity response. This 
would support the notion that at the very least, HE compounds can temporarily halt or 
slow down the progression of the disease. 
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Table 3.1 
Summary of histopathological findings of AD-infected mink subcutaneously treated with HE2300 or HE2500. 
No. of animals displaying 
Pathology Severity Scores 
Treatment 0 + ++ +++ 
HE2500a 3X/wk* 1 2 0 1 
HE2300b lX/wk 0 3 2 0 
HE2300 3X/wk 2 10 5 0 
Vehicle 3X/wk** 2 4 7 1 
Untreated 0 1 5 0 
Normal control 5 0 0 0 
aFluasterone (FLST; 16a-fluoro-5-androsten-17-one; synthetic androstene derivative). 
b~-androstenetriol (~-AET; 5-androstene-3~-7~-triol; natural androsten hormone). 
Percent Animals Positive 








*One animal from this group died from bacterial infections or other causes not attributable pathology. 
**Three animals from this group died from bacterial infections or other causes no attributable AD pathology. 
+: mild, ++: modulate and +++: severe 
--N 
Table 3.2 
Summary of selected physical and physiological parameters eveluated in HE2300- or HE2500-treated mink infected with ADV 
and surviving 8 months. 
Average Pathology Blood Urea Serum 
Weight Severity Nitrogen Creatinine 
Treatment Group Survivors (g ± SD) Scores (-/ +) (mg/di± SD) (mg/dl ± SD) 
HE2500" 3X/wk 3/5 1113 ± 35* 1/2 22.7±17.6 0.4 ± 0.3* 
HE2300b IX/wk 1/5 1060 ± O* 0/1 22±0 0.8 ±0 
HE2300 3X/wk 9/17 1103 ± 34* 2/7 35.9 ± 33.2* 0.8 ±0.3 
Vehicle 3X/wk 1/17 550±0 0/lc 17 ± 0 0.7±0 
Untreated 0/5 0 0/0 0 0 
Normal control 5/5 1360 ± 204 5/0 14.4 ± 4.53 0.7 ± 0.11 
aFluasterone (FLST; 16a-fluoro-5-androsten-17-one; synthetic androstene derivative). 
bp-androstenetriol (P-AET; 5-androstene-3P-7P-triol; natural androsten hormone). 
Serum Alanine Serum Aspartate 
Aminotransferase Aminotransferase 
(U/L± SD) (U/L ± SD) 
118.1 ± 111.4* 91.7 ± 51.3* 
243 ± O* 162 ± O* 
170.3 ± 109.3* 155.7 ± 114.9* 
426 ± 0* 307 ± 0* 
0 0 
42 ± 2.13 42 ± 2.13 
cHistopathological investigation revealed moderate to severe lesions indicative of AD in kidneys and liver (severity score=++). 
*p < 0.01 compared to normal control group. 
--vJ 
Table 3.3 
Detection of viral DNA in mesenteric lymph nodes of AD-infected mink treated subcutaneously with HE2300 or HE2500. 
Pre-Exposure Post-Exposurea 
Treatment Group Presence of Viral Presence of Viral Percent Animals Positive 
DNA (Positive/total) DNA (Positive/total) for Viral DNA 
HE2500b 3X/wk 0/5 1/5 
HE2300c IX/wk 0/5 2/5 
HE2300 3X/wk 0/17 4/17 
Vehicle 3X/wk 0/17 12/17 
Untreated 0/6 5/6 
Normal control 0/5 0/5 
a Represents the lymph node available prior to death or sacrifice of the animal. 
b Fluasterone (FLST; 16a-fluoro-5-androsten-17-one; synthetic androstene derivative). 
c ~-androstenetriol (~-AET; 5-androstene-3~-7~-triol; natural androsten hormone). 
*p ~ 0.01 compared to normal control group. 








Summary of selected viral, serological and immunological parameters evaluated in HE2300- or HE2500-treated mink infected 
with ADV and surviving 8 months. 
Presence of Average Average Average 
viral DNA spleen weight CEP titer CIC titer 
Treatment Group Survivors (-/+) (g ± SD) (± SD) (µg E/ml ± SD) 
HE2500a 3X/wk 3/5 3/0 2.2 ± 0.8 181 ± 129 5.6 ± 1.5 
HE2300b lX/wk 1/5 1/0 2.9 ±0 256± 0 2.1 ± 0 
HE2300 3X/wk 9/17 9/0 2.4 ± 0.6 213 ± 140 2.6 ± 0.1 
Vehicle 3X/wk 1/17 0/1 5.8 ± O* 2048 ± O* 61.6+0* 
Untreated 0/5 0/0 0 0 0 
Normal control 5/5 5/0 2.1 ± 0.5 0 3.8 ±2.2 
aFluasterone (FLST; 16a-fluoro-5-androsten-17-one; synthetic androstene derivative). 
b0-androstenetriol (0-AET; 5-androstene-30-70-triol; natural androsten hormone). 
*p < 0.01 compared to normal control group. 
IFN-y bioactivity 
assay average Nitrite 
serum concentration 
(µM± SD) 
13.8 ± 3.5 
7.8 ± 0 
11.8±3.7 
48.3 ± O* 
0 
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Fig. 3.1. Effects of subcutaneous administration of HE2300 and HE2500 treatment on 
survival time (Kaplan-Meier analysis) of ADV-infected mink. All placebo animals were 
dead after 5 months, generally due to AD. 
*p < 0.05 compared to infected, no treatment. 
**p < 0.01 compared to infected, no treatment. 
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Fig. 3.2. Effect of subcutaneous HE2500 and HE2300 treatment on weight gain of ADV infected mink. All placebo animals were 
dead after 5 months, generally due to AD. 
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Fig. 3.3. Effects of s.ubcutaneous HE2500 and HE2300 treatment on serum ion levels in 
ADV-infected mink. Na+levels (A), er levels (B), Ca+2 levels (C), and K+levels (D). All 
placebo animals were dead after 5 months, generally due to AD. 
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Fig. 3.5. Effects of subcutaneous HE2500 and HE2300 treatment on serum levels of 
blood urea nitrogen (A) and creatinine (B) in ADV-infected mink. All placebo animals 
were dead after 5 months, generally due to AD. 
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Fig. 3.6. Effect of subcutaneous HE2500 and HE2300 treatment on the anti-ADV antibody titers in mink serum taken after 8 months. 
All placebo animals were dead after 5 months, generally due to AD. 













































Fig. 3.7. Effects of subcutaneous HE2500 and HE2300 treatment on detectable immune 
complexes in mink serum taken after 8 months. All placebo animals were dead after 5 
months, generally due to AD. 
D: Pre-virus injection, ■: Sera from last bleed prior to death or sacrifice 
*p < 0.05, **p < 0.01 compared to infected, untreated group. 
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Fig. 3.8. Effects of subcutaneous HE2300 and HE2500 treatment on serum interferon-y activity of mink exposed to Aleutian disease 
virus (taken after 8 months). All placebo animals were dead after 5 months, generally due to AD. 





















































Fig. 3.9. Effects of subcutaneous HE2500 and HE2300 treatment on spleen weight of 
ADV infected mink. The bars represent the average of the spleen weights of mink at 
death or sacrifice for each treatment group. All placebo animals were dead after 5 
months, generally due to AD. 
*p < 0.05, **p < 0.01 compared to infected, untreated group. 
+p < 0.05, ++p < 0.01 compared to infected, vehicle group. 
CHAPTER4 
SUMMARY AND CONCLUSIONS 
ADV Immunological Response 
126 
When ADV is first present in the body, both Thl and Th2 type of immune 
responses are activated. As the infection becomes chronic, there is a shift from the Thl 
to a Th2. For these studies, the immunological response to AD is overwhelmingly 
humoral (hypergammaglobulinemia) and mediated by Th2 type cytokines (especially 
high levels of IL-6). Based on these findings, AD may be a virus-induced cytokine 
disorder; it is a syndrome of chronic, inappropriate production of IL-6 and perhaps other 
Th2-type cytokines. 
A Th 1 immune response is characterized by an inflammatory response with the 
release of IFN-y, IL-2, IL-12, TNF-a, ~' and activation of macrophages and induction of 
CDS+ cytolylic T-cells. It is responsible for clearance of viral and intracellular infections. 
A Th2 immune response can also mediate an anti-inflammatory responses, but is 
better characterized by the stimulation of antibody production by B-cells. It does not 
promote tissue damage as do Thl cells, which release IL-3, 4, 5, 6, and 10. Th2 
predominance leads to the suppression of Th 1 cytokines such as IL-12 and IFN-y. 
Thus, if one could modulate the immune response in AD-infected animals to 
largely cell-mediated response with Thl type cytokines, the severity of AD might 
diminished or perhaps even prevented. Previous immunemodulation studies of AD using 
immunosuppressive therapy has shown slight amelioration of the severity of disease. 
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Two compounds of interest have been shown to modulate the immune system 
towards a Th 1 response: TGF-~ 1 and DHEA; with that in mind we evaluated the effects 
of exogenous human TGF-~ 1 and two DHEA analogs on their ability to diminish the 
severity of AD mink and enhance survival time in mink infected with AD. 
Ameliorating Aleutian Disease in Mink by Treatment 
with Human rTGF-~ 1 
Potential Mechanisms of Inhibition 
(1) TGF-~ 1 may be able to promote Thl cytokine-type response that could afford 
protection for mink from chronic lethal AD. 
(2) Potent effects on immune cells in vitro are reflected in the various effects TGF-~ 1 
has in various animal model systems; Inhibition by TGF-~ 1 is very important in 
mediating immune disorders such as autoimmune disease. 
(3) A finding pertinent to the potential immunotherapy of AD is that exogenous 
administration of TGF-~ 1 in vivo markedly depresses inflammatory and 
immunological responses (e.g., it delays the onset of experimentally induced 
arthritis in mice, a disorder involving immune complexe). 
(4) TGF-~ 1 modulation of Thl and Th2 immune responses. TGF-~ 1 also regulates 
the primary antigen presenting cell (it is activated T lymphocyte responses that 
are responsible for correct processing of virus antigen). Thus, it has a regulatory 
role in the differentiation of T cells (expression of CD8+ ). It also, it strongly 
promotes the generation of Thl cells. Thus, it is conceivable that TGF-~ 1 could 
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elicit a Thl response adequate enough to ameliorate AD by inducing appropriate 
processing of AD antigen. 
(5) TGF-~ 1 inhibition of to B cell proliferation. TGF-~ 1 inhibits B cell proliferation 
and is able to induce apoptosis (programmed cell death) in B cells in addition to 
reducing the secretion of immunoglobulin from activate B cells. These 
mechanisms suggest that TGF-~ 1 may be able down-regulate a B cell hyper 
response such as seen in mink with AD. 
(6) TGF-~ 1 inhibition of antibody class switching. Early hematopietic growth and 
differentiation alters B cell lg production and class switching, and inhibits mast 
cell, thymocyte, B cell and T lymphocyte proliferation 
Summary of Results Nine Months (266 days) 
after Exposure to ADV 
(1) TGF-~ 1 treated animals had an increase of nearly two-fold in survival time 
compared to infected placebo-treated or untreated animals (Table B.1). 
(2) TGF-~ 1 treated animals had an increase of nearly two-fold in body weight 
compared to infected untreated animals (Table B.2). 
(3) TGF-~ 1 treated animals showed a dramatic decrease in ADV-specific antibody 
titers compared to placebo-treated or untreated infected animals. BUN, IFN-y, 
and CIC levels were well within normal parameters (Table B.3, B.4, and B.5), . 
(4) TGF-~ 1 treated animals had a two-fold increase body weight compared to infected 
placebo-treated or untreated animals, although they lost weight compared to their 
initial weight. 
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Conclusions: Analysis of the Mink Treated with TGF-/J1 
(1) TGF-~ 1 at 100 or 200 ng/kg regimen was most effective in treating ADV-infected 
mink; both doses appeared to delay the progression of the disease (Table B.6 and 
B.7). 
(2) TGF-~ 1 at 1 ng/kg regimen failed to protect most mink from lethal chronic AD. 
(3) Treatment with LAPrhTGF-~ 1-inhibitor at 500 ng/kg regimen resulted in high 
physical, physiological and immunological parameter levels in the AD-infected 
mink; the kidneys were damaged by immune complex deposition, a hallmark of 
AD. 
(4) These findings support the hypothesis that TGF-~ 1 treatment of mink by inguinal 
vein injection can ameliorate AD in mink. 
Effects of HE2300 and HE2500 on the Outcome of 
Aleutian Disease in Mink 
Potential Mechanisms of Inhibition 
(1) DHEA, an epiandsterone increases the levels of Thl cytokines, IL-2, IL-3, and 
IFN-y and counteracts hydrocortisone-mediated immune suppression that could 
afford protection for mink from chronic lethal AD. 
(2) HE2300 (~-ABT), a natural androstene, up-regulates immunity, which increases 
resistance against lethal infection and lethal radiation, and mediates a rapid 
recovery of hematopoietic precursor cell after radiation injury 
(3) HE 2300 protects the host from lethal infection by DNA or RNA viruses such as 
herpesvirus type 2, coxsackie virus B4, influenza, and arthropod borne viruses. In 
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addition, mortality from a lethal challenge of human enteric virus was reduced by 
50% when animals were treated with HE2300. 
( 4) DHEA has been shown to have general immunomodulating effects in 
experimental infections involving viruses. 
(5) DHEA shifts cytokine production to a Thl response and increases circulating 
activated immune effects or cells in HIV infections. 
Summary of Results Eight Months After Exposure to ADV 
(1) HE2500 and 2300 (3x/week) treatment increased survival time and body weight 
nearly two-fold compared to infected, untreated animals (Table C.2). 
(2) HE2500 and 2300 (3x/week) treated animals showed a dramatic decrease in 
ADV-specific antibody titers, and BUN, creatinine, ALT, AST, IFN-y, and CIC 
levels werelowered in treated animals (Table C.3, C.4, and C.5). 
(3) In contrast, untreated and placebo-treated animals had high antibody titers and 
high BUN, creatinine, ALT, AST, IFN-y, and CIC levels, suggesting immune 
complex deposition, a hallmark of AD. This was supported by histopathological 
examination of the kidney and liver tissues of the mink. 
(4) Spleen weights of untreated and placebo-treated animals increased by two-fold 
compared to treated animals and control mink. 
(5) PCR assay of lymph node tissue demonstrated that virus DNA could be detected 
in 83% of the untreated and placebo-treated AD-infected mink, whereas it was 
only detected in 18% of drug-treated animals (Fig. C.1). 
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Conclusions: Analysis of The Mink Treated with HE2300 and HE2500 
(1) A three times per week dosage regimen of HE2500 and 2300 at 16 ng/k:g dosage 
was the most effective means of treating ADV-infected mink; both compounds 
appeared to delay the progression of the disease. 
(2) A one time per week regimen of HE2300 failed to protect most mink from lethal 
chronic AD. 
(3) The kidneys and liver of vehicle were damaged by immune complex deposition, a 
hallmark of AD. 
(4) These findings tend to support the hypothesis that 13-androstene analog treatment 
of mink by subcutaneous injection can ameliorate Aleutian disease in mink. 
Summary of Conclusion for Both Treatments (TGF-f31 
and HE 2300/ 2500) 
(1) DHEA (analogs) and TGF-131 may be able to promote Thl cytokine-type response 
that could afford protection for mink from chronic lethal AD. 
(2) TGF-131 at 200 and 100 ng/k:g treatment temporarily slowed down the progression 
of the disease. 
(3) A three times per week regimen of HE2500 and 2300 was effective in treating 
ADV-infected mink; both compounds temporarily halted or slowed down the 
progression of the disease. 
(4) These findings support the hypothesis tested in this research that TGF-131 
treatment of mink by inguinal vein injection and 13-androstene analog-treatment of 
mink by subcutaneously injection can ameliorate Aleutian disease in mink. 
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APPENDICES 
Appendix A. Experimental Methods of Ameliorating Aleutian 
Disease in Mink by Treatment with Human rTGF-~ 1 
Table Al. 
Study Design for TGF-~ 1 treatment of ADV-infected mink. 
Treatment Group 
Grou12 1 Grou12 2 Grou12 3 Grou12 4 
Mink injected Mink injected Mink injected Mink injected 
2 weeks 8h 2 weeks 3 treatmentsa 
Treatment Pre-virus Post-virus Post-virus 
inoculation inoculation inoculation 
TGF-~ 1 200 ng/kg 5 5 5 5 
TGF-~ 1 100 ng/kg 5 5 5 0 
TGF-~ 1 1 ng/kg 5 5 5 0 
TGF-~ 1-lnhibitol 5 5 5 0 
Placeboc 5 5 5 0 
Total 25 25 25 5 









bLatency associated peptide, recombinant human (LAPrhTGF-~1 at 500 ng/kg). 










Fig. A.2. These pictures depict blood collection method. 
AD Virus Inject 
-- -
Group 1 
Treated with TGF-~ 1 injected 
2 weeks pre-virus inoclation 
l 
Group 2 
Treated with TGF-~ 1 injected 
8 h post-virus inoclation 
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Group 3 
Treated with TGF-~ 1 inject d 
2 weeks post-virus inoclati n 
Group 4 I (TGF-~1 injected 3 times) 
Fig. A.3. TGF-~ 1 injection time interval. All animals were injected intraperitoneally (IP) 
with a 1: 500 dilution of Aleutian disease virus of mink (strain Utah I) in 0.1 % PSS and 
each mink receiving 1ml viral dilution mixture per kilogram body mass. 
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(A) (B) 




Fig. A.5. These figures depict CEP assay. Runs 1 % agarose gel, 55V, 1 hours. 
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Appendix B. Tables and figures of Ameliorating Aleutian Disease in Mink by 
Treatment with Human rTGF-(3. 
Table B.1 
Effect of intravenous TGF-~ 1 treatment on survival time of mink with Aleutian disease. 
Mean Survival Time a 
Group No. Treatment Survivors (days± SD) 
Group 1 TGF-[31 200 ng/kg 3/5* 207 ± 21 * 
( treated 2 weeks TGF-f31 100 ng/kg 3/5* 221 ± 26* 
pre-virus TGF-f31 1 ng/kg 1/5 170 ± 31 
inoculation) TGF-[31-Inhibitor 0/5 116 ± 9** 
Placebo 0/5 149± 8 
Group 2 TGF-[31 200 ng/kg 3/5* 204 ± 9* 
(treated 8 h TGF-[31 100 ng/kg 3/5* 247 ± 17* 
post-virus TGF-[31 I ng/kg 1/5 170 ± 38 
inoculation) TGF-[31-Inhibitor 0/5 123 ± 12 
Placebo 0/5 120 ± 25 
Group 3 TGF-[31 200 ng/kg 2/5 200 ± 33* 
( treated 2 weeks TGF-[31 100 ng/kg 3/5* 223 ± 28** 
post-virus TGF-[31 1 ng/kg 1/5 179 ± 31 
inoculation) TGF-f31-Inhibitor 0/5 135 ± 26 
Placebo 0/5 129 ± 24 
Group 4 TGF-f31 200 ng/kg 3/5* 248±31** 
(3 treatmentsl Placebo 0/5 133 ± 19 
a Animals dying prior to day 266 days 
bTGF-[31 was administered 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation. 
*p < 0.05 compared to placebo-treated controls. 
**p < 0.01 compared to placebo-treated controls. 
Table B.2 
Effect of intravenous TGF-~ 1 treatment on body weights of mink with Aleutian disease. 
Mean Bod}'. Weight (g ± SD) 
Group 1 (treated 2 weeks Group 2 (treated 8 h Group 3 (treated 2 weeks Group4 
12re-virus inoculation) 12ost-virus inoculation) 12ost-virus inoculation (3 treatmentst 
Pre-virus Post-virus Pre-virus Post-virus Pre-virus Post-virus Pre-virus Post-virus 
Treatment Exposure Exposure b Exposure Exposure Exposure Exposure Exposure Exposure 
TGF-B1 200 ng/kg 1040 ± 33 828 ± 87* 1035 ± 17 808 ± 65*f 1028 ± 52 788 ± 103* 1073 ± 53 969 ± 103* 
TGF-B1 100 ng/kg 1040 ± 84 820 ± 114* 1008 ± 38 883 ± 94* 1024 ± 58 853 ± 100* NDC 
TGF-B1 1 ng/kg 1038 ± 48 730 ± 120* 1025 ± 68 765 ± 145 1040 ± 52 655 ± 53*f NDC 
TGF-B1-Inhibitor 1050 ± 67 340 ± 22+ 1075 ± 73 373 ± 22*f 1050 ± 53 380 ± 3r NDC 
Placebo 1080 ± 37 339 ± 24+ 1025 ± 66 470 ± 60+ 1033 ± 43 365 ± 39+ 1046 ± 49 391 ±41+ 
aTGF-~ 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation. 
bRepresents the last weight available prior to death or sacrifice of the animal. 
cND = Not Done 
*p ::; 0.05 compared to placebo-treated controls. 





Effect of intravenous TGF-~ 1 treatment on the anti-ADV antibody titers of mink with Aleutian disease. 
Mean Reciprocal Antibody Titers 3 ± SD 
Group 1 (treated 2 weeks Group 2 (treated 8 h Group 3 (treated 2 weeks 
Treatment pre-virus inoculation) post-virus inoculation) post-virus inoculation 
TGF-~ 1 200 ng/kg 358 ± 64** 410 ± 64** 307 ± 57** 
TGF-~ 1 100 ng/kg 307 ± 57** 218 ± 43** 327 ± 88** 
TGF-~, 1 ng/kg 614 ± 150* 563 ± 140** 666 ± 128* 
TGF-~ 1-lnhibitor 1126 ± 280 1024 ± 0 922 ± 115 
Placebo 1024 ± 0 922 ± 115 1126 ± 280 
3Represents data from the last serum sample taken prior to death or sacrifice of the animal. 
bTGF-~1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation 
cND = Not Done 
*p ~ 0.05 compared to placebo-treated controls. 
**p ~ 0.01 compared to placebo-treated controls. 
Group 4 
(3 treatmentsl 








Effect of intravenous TGF-~ 1 treatment on blood urea nitrogen (BUN) levels in mink with Aleutian disease. 
Mean BUN levels (mgldL ± SD) 
Group 1 (treated 2 weeks Group 2 (treated 8 h Group 3 (treated 2 weeks 
2re-virus inoculation) 2ost-virus inoculation) 2ost-virus inoculation 
Pre-virus Post-virus Pre-virus Post-virus Pre-virus Post-virus 
Treatment Exeosure Exposure 
b Exeosure Exeosure Exeosure Exeosure 
TGF-~1 200 ng/kg 6.21 ± 1.23 17.86 ± 4.90* 6.83 ± 3.68 23.10 ± 5.20* 8.30 ± 2.46 22.77 ± 4.47* 
TGF-~1 100 ng/kg 5.15 ± 1.29 14.14 ± 3.51 * 7.98 ± 1.66 15.25 ± 3.40* 8.07 ± 1.23 15.08 ± 6.96* 
TGF-~ 1 1 ng/kg 5.46 ± 2.38 31.32 ± 6.96*t" 6.75 ± 1.76 33.15 ± 11.84 8.54 ± 2.54 29.15 ± 8.15* 
TGF-~1-Inhibitor 7.08 ± 1.23 84.07 ±17.43+ 7 .53 ± 1.45 73.15 ± 18.3+ 5.39 ± 1.69 61.81 ± 15.74+ 
Placebo 5.48 ± 2.02 63.83 ± 12.68+ 5.29 ± 1.64 56.59 ± 9.20+ 7.70 ± 1.98 67.55 ± 5.03+ 
aTGF-~ 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation 
bRepresents data from the last serum sample taken prior to death or sacrifice of the animal. 
cND = Not Done 
*p ::; 0.05 compared to placebo-treated controls. 













Effect of intravenous TGF-~ 1 treatment on serum interferon gamma (IFN-y) levels in mink with Aleutian disease. 
Mean lnterferon-y levels (l::!:M ± SD) 
Group 1 (treated 2 weeks Group 2 (treated 8 h Group 3 (treated 2 weeks 
2re-virus inoculation) 2ost-virus inoculation) 2ost-virus inoculation 
Pre-virus Post-virus Pre-virus Post-virus Pre-virus Post-virus 
Treatment Exposure Exposure b Exposure Exposure Exposure Exposure 
TGF-~ 1 200 ng/kg 6.36 ± 0.86 18.13 ± 3.31*t" 7.08 ± 1.06 15.48 ± 5.60* 6.76 ± 2.76 16.63 ± 2.42*f 
TGF-~ 1 100 ng/kg 5.86±1.10 11.97 ± l.74*f 7.26 ± 1.71 17.60 ± 4.90*f 8.01 ± 2.20 16.89 ± 3.60*f 
TGF-~ 1 1 ng/kg 5.64 ± 0.84 24.99 ±4.20+ 6.25 ± 1.84 25.03 ± 5.32*f 7.06±2.16 23.90 ± 8.76+ 
TGF-~ 1-Inhibitor 5.41 ± 0.96 40.93 ± 6.99+ 6.81 ± 1.85 39.83 ± 6.22+ 6.22 ± 1.60 50.41 ± 10.99+ 
Placebo 6.05 ± 1.51 31.60 ± 2.81+ 5.81 ± 1.27 37.29 ± 4.24+ 6.65 ± 1.81 42.00 ± 11.26+ 
aTGF-~ 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation 
bRepresents data from the last serum sample taken prior to death or sacrifice of the animal. 
cND = Not Done 
*p ~ 0.05 compared to placebo-treated controls. 














Effect of intravenous TGF-~ 1 treatment on average of serum TGF-~ 1 levels in mink. 
Mean TGF-~ 1 levels (ng/ml ± SDl 
Group 1 (treated 2 weeks Group 2 (treated 8 h Group 3 (treated 2 weeks 
2re-virus inoculation) 2ost-virus inoculation) 2ost-virus inocul<!tion 
Baseline Baseline Baseline 
Treatment levels Ave. levels Ave. levels Ave. 
TGF-~ 1 200 ng/kg 1.08 0.95 ± 0.07* 0.78 0.88 ± 0.11 * 0.79 0.84 ± 0.11 * 
TGF-~ 1 100 ng/kg 1.02 0.91 ± 0.06* 0.78 0.88 ± 0.07* 0.77 0.84 ± 0.06* 
TGF-~ 1 1 ng/kg 0.82 0.77 ± 0.02 0.78 0.77 ± 0.03 0.79 0.77 ± 0.03 
TGF-~ 1-lnhibitor 0.58 0.55 ± 0.07* 0.78 0.67 ± 0.03 0.80 0.62 ± 0.11 * 
Placebo 0.87 0.73 ± 0.05 0.80 0.73 ± 0.04 0.77 0.74 ± 0.02 
aMean levels after death or at sacrifice. 
bTGF-~1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation. 
cND = Not Done 













Effect of intravenous TGF-~ 1 treatment on serum TGF-~ 1 levels in mink. 
Mean TGF-@1 levels (ng/ml ± SD) 
Pre-virus Time months virus ex2osure 
Group No. Treatment Exposure 8h 1 2 3 4 5 6 7 8 
--
Group 1 TGF-[31 200 ng/kg 1.08±0.16 1.04±0.10 0.98±0.03 0.95±0.08 0.95±0.07 0.91±0.06 0.91±0.10 0.93±0.03 0.83±0.00 0.92±0.00 
(2 weeks TGF-[31 100 ng/kg 1.02±0.11 1.02±0.11 0.92±0.01 0.92±0.05 0.90±0.04 0.88±0.03 0.91±0.04 0.89±0.09 0.85±0.03 0.85±0.03 
pre-virus TGF-[31 1 ng/kg 0.82±0.08 0.79±0.08 0.78±0.07 0.78±0.10 0.76±0.08 0.77±0.05 0.77±0.09 0.77±0.04 0.74±0.08 0.76±0.07 
inoculation) TGF-[31-lnhibitor 058t0,05 0.54±0.21 0.55±0.08 0.57±0.10 0.51±0.03 0.52±0.00 
a 
Placebo 0>81±0.08 0.70±0.08 0.78±0.08 0.75±0.09 0.73±0.05 0.72±0.04 0.64±0.00 
Group 2 TGF-[31 200 ng/kg 0.79±0.08 It™ 1.00±0.04 0.93±0.07 0.87±0.10 0.83±0.09 0.85±0.03 0.82±0.06 0.75±0.00 .,;, --~ffi 
(8 h post- TGF-[31 100 ng/kg 0.78±0.06 r 0±011 0.97±0.10 0.91±0.10 0.89±0.12 0.91±0.09 0.86±0.10 0.78±0.06 0.84±0.02 0.82±0.07 
virus TGF-[31 1 ng/kg 0.78±0.05 obJi~9 0.78±0.07 0.76±0.06 0.81±0.05 0.82±0.05 0.79±0.06 0.74±0.06 0.72±0.03 0.75±0.06 
inoculation) TGF-[31-Inhibitor 0.78±0.05 0'.69\0:O9 0.68±0.07 0.66±0.06 0.61±0.05 0.62±0.05 0.69±0.06 0.64±0.06 ,, ,n. '1ft : -, 
Placebo 0.80±0.09 • o:1<£~fo9· 0.73±0.04 0.68±0.02 0.72±0.0 5 0.67±0.00 
Group 3 TGF-[31 200 ng/kg 0.79±0.09 0.78±0.09 1.07±0.10 0.97±0.12 0.91±0.11 0.84±0.11 0.79±0.05 0.77±0.07 0.76±0.10 0.72±0.01 
(2 weeks TGF-[31 100 ng/kg 0.77±0.05 0.75±0.05 0.~5±0:13 0.89±0.13 0.88±0.10 0.85±0.01 0.83±0.03 0.81±0.04 0.84±0.06 0.83±0.06 
post-virus TGF-[31 1 ng/kg 0.79±0.03 0.77±0.03 0.82±0,03 0.77±0.07 0.75±0.02 0.77±0.12 0.75±0.09 0.75±0.03 0.73±0.01 0.76±0.00 
inoculation) TGF-[31-Inhibitor 0.80±0.05 0.77±0.04 0.56±0.08 0.54±0.10 0.53±0.06 0.56±0.03 0.61±0.03 
Placebo 0.77±0.05 0.74±0.08 0.75±0:06 0.66±0.07 0.62±0.06 0.66±0.08 0.62±0.03 
::. iv. 
~ ,..,, 
Group 4b TGF-[31 200 ng/kg 1.06±0.10 1.3slo:o8 1.59£0:17 1.27±0.11 1.04±0.05 0.96±0.11 0.86±0.07 0.84±0.01 0.87±0.01 0.81±0.04 
3 treatment 
aAnimal was already dead prior to this sampling time. 
b2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation. 






Fig. B.l. Detection of ADV DNA in mink treated with TGF-~ 1• The expected fragment size was 379 base pairs, representing 
nucleotides 224-602. Group 1: treated with TGF-~ 1 injected 2 weeks pre- (A), Group 2: 8 hours post- (B), Group 3: 2 weeks after-
virus inoculation (C), and Group 4: TGF-~ 1 injected 3 times (2 weeks pre-, 8 h post-, and 2 weeks post- virus inoculation) (D). 
Lane 1-5: TGF-~ 1 at 200 ng/kg, 6-10: 100 ng/kg, 11-15: 1 ng/kg, 16-20: rhLAPTGF-~ 1 at 500ng/kg (inhibitor) and 21-25: PSS in 
0.1 % BSA. +: positive control (379 base pairs) , -: negative control and ST: 100kb DNA ladder. PCR assay of lymph node tissue 




Appendix C. Tables and figure of Effects of HE2300 and 
HE2500 on the Outcome of Aleutian Disease in Mink 
Study Design for DHEA treatment of ADV-infected mink. 
Treatment Received Compound Number of 
animals 
Infected, HE2500a 16 ng/kg, 3 times per week received 5 
Infected, HE2300b 16 ng/kg, one times per week received 5 
Infected, HE2300 16 ng/kg, 3 times per week received 17 
Infected, Vehiclec 16 ng/kg, 3 times per week received 17 
Infected, untreated Virus with untreated 6 
Normal Control No virus, untreated 5 
Total 55 
148 
aFluasterone (FLST); 16a-fluoro-5-androsten-17-one; synthetic androstene derivative. 
b~-androstenetriol (~-ABT); 5-androstene-3~-7~-triol; natural androsten hormone. 
Table C.2. 























Mean Time to Death 
(months± SD) 
5.8 ± 3.2 
4.0 ± 2.4** 
5.7 ± 2.6 
4.0 ± 2.2** 
3.8 ± 1.5** 
8.0±0 
alncludes only those animals that demonstrated pathology attributable to Aleutian disease. 
bFluasterone (FLST); 16a-fluoro-5-androsten-17-one; synthetic androstene derivative 
c B-androstenetriol (B-AET); 5-androstene-3B-7B-triol; natural androsten hormone. 
*p < 0.001 compared to normal control animals. 
**p = 0.016 compared to normal control animals. 
Mean Time to Death 
(months ± SD; Adjusteda) 
7.0± 2.0 
4.0 ± 4.0** 
5.7 ± 2.6 
4.5 ± 2.5** 






Effects of subcutaneous HE2500 and HE2300 treatment on serum ion levels in ADV-infected mink. 
Na+(mmol/L± SD) Ca +z (mg/dL ± SD) K+ (mmol/L± SD ) 
Treatment Group Pre- After Virus Pre- After Virus Pre-
Exposure Exposurea Exposure Exposure" Exposure 
HE2500b 3X/wk 148 ± 5.6 143 ± 5.1 10.2 ± 0.9 9.7 ± 1.88 6.4 ± 0.5 
HE2300c IX/wk 151 ± 4.8 144 ± 5.0 10.1 ± 0.9 10.1 ± 1.3 6.1 ± 0.6 
HE2300 3X/wk 149 ± 4.6 144 ± 3.7 10.0 ± 0.5 10.0 ± 1.0 6.1 ± 0.9 
Vehicle 3X/wk 145 ± 4.7 161 ± 4.2 10.1 ± 0.8 7.o ± L3*r 7.9 ± 0.8 
Untreated 150±2.1 166 ± 4.3 10.4 ± 0.4 8.2 ± 2.7 7.6 ± 0.7 
Normal control 149 ± 3.0 146 ± 5.1 9.9 ± 0.9 10.0 ± 0.9 5.0 ± 0.5 
aRepresents the last serum available prior to death or sacrifice of the animal. 
bFluasterone (FLST; 16a-fluoro-5-androsten-17-one; synthetic androstene derivative). 
c~-androstenetriol (~-AET; 5-androstene-3~-7~-triol; natural androsten hormone). 
*p < 0.05 compared to normal control animals. 
+p < 0.05 compared to pre- vs. post-virus exposure. 
After Virus 
Exposurea 
4.9 ± 0.9 
4.9 ± 0.8 
4.9 ± 0.8 
7.1 ± 0.9* 
6.7 ± 0.8* 
4.9 ± 0.3 
er (mmol/L ± SD ) 
Pre- After Virus 
Exposure Exposure a 
116 ± 6.2 108 ± 5.4 
116 ± 4.8 108 ± 5.5 
118 ± 4.9 111±5.2 
117±5.5 130 ± 5.3* 
121 ± 7.1 132 ± 6.8* 




Effects of subcutaneous HE2500 and HE2300 treatment on serum liver enzyme levels of ADV-infected mink. 
Alanine Aminotransferase(U/L ± SD) Aspartate Aminotransferase (U/L ± SD) 
Treatment Group 
Pre-Exposure After Virus Exposurea Pre-Exposure 
HE2500b 3X/wk 40 ± 8.47 65 ± 17.14 54 ± 9.13 
HE2300c lX/wk 33 ± 4.97 101 ± 26.22*f 52 ± 12.24 
HE2300 3X/wk 34 ± 7.54 79 ± 33.34+ 49 ± 36.7 
Vehicle 3X/wk 40 ± 11.13 194 ± 85.73*f 62 ± 38.74 
Untreated 43 ± 9.63 220 ± l 19.4*f 58 ± 36.0 
Normal control 41 ± 4.44 42 ± 2.13 39 ± 6.02 
aRepresents the last serum available prior to death or sacrifice of the animal. 
bFluasterone (FLST; 16a-fluoro-5-androsten- l 7-one; synthetic androstene derivative). 
cf3-androstenetriol (f3-AET; 5-androstene-3 f3-7f3-triol; natural androsten hormone). 
*p < 0.05 compared to normal control animals. 
+p < 0.05 compared to pre- vs. post-virus exposure. 
After Virus Exposurea 
74 ± 10.21 * 
102 ± 17.26*f 
80 ± 19.56* 
132 ± 68.53*f 
174 ± 50.60*f 
42 ± 2.13 
-UI -
Table C.5 
Effects of subcutaneous HE2500 and HE2300 treatment on serum levels of blood urea nitrogen and creatinine in ADV-infected 
mink. 
Blood Urea Nitrogen (mg/dl ± SD) Creatinine (mg/dl ± SD) 
Treatment Group Pre-Exposure After Virus Exposurea Pre-Exposure 
HE2500b 3X/wk 22 ± 5.07 22 ± 4.38 1.3 ± 0.2 
HE2300c lX/wk 24.8 ± 6.50 26.7 ± 4.99* 1.6 ± 1.5 
HE2300 3X/wk 23.8 ± 6.02 25.8 ± 5.83 1.2 ± 0.7 
Vehicle 3X/wk 27.7 ± 10.61 34.5 ± 15.37* 1.4 ± 0.4 
Untreated 25.5 ± 10.68 40.8 ± 12.02*r 0.5 ± 0.5 
Normal control 15.0 ± 9.4 14.4 ± 4.53 0.9 ± 0.2 
aRepresents the last serum available prior to death or sacrifice of the animal. 
bFluasterone (FLST; 16a-fluoro-5-androsten-17-one; synthetic androstene derivative). 
c~-androstenetriol (~-AET; 5-androstene-3~-7~-triol; natural androsten hormone). 
*p < 0.05 compared to normal control animals. 
+p < 0.05 compared to pre- vs. post-virus inoculation. 
After Virus Exposurea 
0.9 ± 0.18 
1.4 ± 0.36* 
1.1 ± 0.29 
2.4 ± 1.01 *r 
3.1 ± 1.28*r 






Fig. C. 1. Detection of ADV DNA in mink treated with HE2300 and HE2500. (A) Lane 1-
5: Infected/HERF 2300 lx/wk, 6-10: lnfected/HERF 2500 lx/wk, (B) Lane 45-50: 
Infected/untreated, 51-55: Normal control, (C) Lane 11-27: Infected/HERF 2300 3/week 
and (D) Lane 28-44: Infected/vehicle 3x/wk. S: DNA ladder lO0bp, +: AD positive 
control and-: AD negative control. 
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